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The truth may be puzzling. It may take some work to grapple with. It may be 
counterintuitive. It may contradict deeply held prejudices. It may not be 
consonant with what we desperately want to be true. But our preferences do 
not determine what's true. We have a method, and that method helps us to 
reach not absolute truth, only asymptotic approaches to the truth — never 
there, just closer and closer, always finding vast new oceans of undiscovered 
possibilities. 
 
Carl Sagan in "Wonder and Skepticism", Skeptical Inquirer 19 (1), January-
February 1995, ISSN 0194-6730 
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1 ABSTRACT 
Parvoviruses are single-stranded DNA viruses that infect both vertebrates and 
insects. They are among the smallest viruses known with a diameter of only 18-
26 nm and a genome of 4-6 kb. Since 2005, six new species of human 
parvoviruses have been reported, quadrupling the number of known human 
parvoviruses to eight. Among these are four human bocaviruses (HBoV1-4). 
HBoV1 was discovered in human respiratory specimens and is likely to cause 
respiratory disease in young children. In contrast, HBoV2-4 were discovered in 
human stool specimens and HBoV2 has been tentatively associated with acute 
gastroenteritis. At the moment there are too little data to evaluate the 
associations of HBoV3 or HBoV4 with human disease.  
 To facilitate the diagnostics of HBoV1-4 infections, we developed a 
multiplex real-time PCR method for their detection in a single reaction (Study 
I). Differentiation and precise quantitation of the individual bocaviruses can be 
subsequently achieved with singleplex PCRs that are based on the same primers 
as the multiplex reaction, or by sequencing. These newly developed PCR 
methods were shown to be highly specific and sensitive, with detection limits of 
<10 copies/reaction. The assays were used to assess the prevalence of HBoV1-4 
DNA in 250 Finnish adults and children with gastrointestinal symptoms. 
HBoV2 was detected in four (1.6%) subjects, HBoV3 in one (0.4%) whereas no 
HBoV1 or HBoV4 DNAs were detected. All four HBoV2-positive children were 
<2 years of age. In this age group of 20 children, HBoV2 prevalence was as high 
as 20%. Together with earlier studies, these findings support the conclusion that 
HBoV2 infections are common among young children but rare among adults. 
 To expand the tool repertoire in the diagnosis of HBoV infections 
and to study the immunology of these novel viruses, antibody assays based on 
HBoV capsid proteins VP2 and VP1 were developed. These proteins are derived 
from overlapping reading frames and are identical except for an additional ~130 
amino acids on the amino terminus of VP1. Immunoblotting showed that, in 
denatured form, HBoV1 VP2 capsid protein was superior in immunoreactivity to 
the non-overlapping or "unique" portion of VP1 (VP1u; Study II). This finding 
was surprising since human parvovirus B19 VP1u is very immunoreactive and 
useful in the diagnostics of B19. Immunoblot analysis of paired serum samples 
from children with acute wheezing showed that primary, symptomatic HBoV1 
  7 
infections frequently result in viremias, elicit B cell immune responses and can 
be diagnosed using serology. Enzyme immunoassays (EIAs) based on 
conformational virus-like particles (VLPs) were also developed to refine our 
understanding of human bocavirus epidemiology (Study III). It was found that 
HBoV1-4 antibodies are cross-reactive and correction for cross-reactivity is a 
prerequisite for accurate VLP-based HBoV seroepidemiology. 
 In Study IV, the newly developed antibody and DNA assays were 
used to assess the incidences of HBoV1-4 primary infections among 
constitutionally healthy Finnish children. The incidence of HBoV1-4 viremias 
and the stability of HBoV1-4 IgG responses were also studied. The study 
population consisted 109 children of whom serum samples (n=1961) were 
collected with 3 to 6 month intervals, starting from infancy and up to 13 years of 
age.  All children became seropositive for one or more human bocaviruses by the 
age of 5 years. The median HBoV1-3 IgG seroconversion ages were 1.7 to 1.9 
years. IgG seroconversions for HBoV1-4 were observed in 86%, 53%, 10% and 
0% of the children, respectively. Typically HBoV1 IgG levels remained high 
throughout the follow-up period, whereas HBoV2 IgG levels were markedly 
lower and characterized by waning and sharp fluctuations. In contrast to acute 
HBoV1 infections that appear to be mostly viremic, primary HBoV2 infections 
were found to be rarely associated with viremia or to be short in duration.  
HBoV1 IgG seroconversions were rarely detected in children who 
had HBoV2 IgG and vice versa. In children who nevertheless had IgG towards 
both viruses, antibody responses to the second infecting virus were typically 
very weak. This weakness of secondary IgG responses was evident in most of the 
9 children who had antibodies for one bocavirus species before showing viremia 
for another species. Of these nine children, seven did not develop detectable 
levels of specific antibodies against the second infecting bocavirus. Put together, 
these results indicate that priming with one bocavirus species may inhibit 
generation of antibodies toward the novel epitopes of another bocavirus species, 
a phenomenon known as “original antigenic sin” (OAS). Alternatively, or 
possibly intertwined with OAS, infection with one bocavirus species may result 
in cross-protective immunity against other bocavirus species. This weakness or 
absence of secondary HBoV antibody responses should be taken into 
consideration when diagnosing HBoV infections serologically.  
 
List of original publications 
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4 FOREWORD 
Obstetricians and an occasional dog owner recognize the word "parvovirus" and 
are aware of the serious infections that these pathogens may cause in human 
fetuses or canine puppies. However, few are aware that there are more than 50 
parvovirus species that can infect at least 12 vertebrate species and multiple 
invertebrate species, ranging from bovines to moths. It is impossible to tell how 
many exciting new parvoviruses are yet to be found; at least 14 new species have 
been reported during the last 8 years alone. On average that is almost two new 
species per year! 
 Due to the vast size of the virus family, most of the fascinating 
world of parvoviruses falls outside the scope and limits of this thesis. The 
literature review therefore focuses almost entirely on the parvovirus genus 
Bocavirus. The interested reader who wishes to explore other aspects of 
parvoviruses is encouraged to read the excellent book “Parvoviruses”, edited by 
Jonathan Kerr, Marshall Bloom, Susan Cotmore, Michael Linden and Colin 
Parrish. 
 The first human bocavirus, HBoV1, was discovered in 2005 and 
three more species, HBoV2-4, were reported in 2009 and 2010. Relatively little 
research data has yet accumulated on the latter three viruses. To put the scarce 
clinical data from humans into context with the known features of other 
bocaviruses, the first chapter of the literature review investigates the closest 
pathogenetically characterized relatives of HBoV1-4, the bovine and canine 
bocaviruses.  This also provides unique, tissue-level viewpoints into the 
pathogenesis of bocavirus infections that would be infeasible in human studies. 
 The second chapter of the literature review deals specifically with 
human bocaviruses. The focus is on the DNA-based diagnostics of HBoV 
infections and their clinical significance. Serological aspects of HBoV 
diagnostics are addressed in the Results & Discussion section.  
 The third and the last chapter of the literature review discusses 
immunological phenomenon known as original antigenic sin, i.e. the propensity 
of the immune system to utilize immunological memory based on a previous 
infection when a second slightly different version of a virus (or another antigen) 
is encountered. Original antigenic sin may have an important role in human 
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bocavirus immunology and therefore good understanding of the phenomenon 
may be essential for interpreting the results of this thesis. 
 As the last introductory note to the reader, the results section 
contains a reference to an online supplementary PDF file. The file summarizes 
327 graphs of the serological results of Study IV. The contents of the file are not 
essential for the understanding of the thesis but may provide thought-provoking 
information to an interested reader. The online location of the file is not 
provided as a typical Internet address ("URL") but rather as a digital object 
identifier (DOI), since the former can change over time but the latter is 
permanent. The DOI code can be translated into a URL at dx.doi.org to gain 
access to the file, which is hosted by LabArchives Ltd. The company asserts to 
provide permanent storage of scientific data to scientific journals and individual 
scientists alike. 
 
Review of the literature 
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5 REVIEW OF THE LITERATURE 
5.1 INTRODUCTION TO PARVOVIRUSES 
5.1.1 HISTORY 
Parvoviruses are among the smallest DNA viruses to infect mammalian cells. 
The icosahedral capsid has a diameter of only 21.5 [1]  to 25.5 nm [2], i.e. 
roughly 300 times the diameter of a carbon atom, currently only surpassed in 
minuteness by some circovirus species. Hence the name parvo, originating form 
the Latin word parvum and meaning small. 
 The first vertebrate parvovirus was isolated from a rat in 1959 and 
the first invertebrate parvovirus from a moth in 1964. The mid-1960s also saw 
the discovery of adeno-associated viruses, a group physically similar to the 
rodent and invertebrate parvoviruses but dependent upon adenovirus co-
infection for their own replication. The name “parvovirus” was introduced to the 
literature in 1966 and the taxonomic family Parvoviridae was established by the 
International Committee on Taxonomy of Viruses (ICTV) in the 1970’s [3].  
5.1.2 TAXONOMY & PHYLOGENY 
Until the late 90’s, ICTV classification of parvoviruses into genera emphasized 
their biological and structural characteristics [3]. These criteria included factors 
such as the number of promoters in the virus genome, capability to replicate 
autonomously without a helper virus and the type of single stranded DNA 
(sense or antisense) that is packaged in the virion [3]. In 2001, Lukashov and 
Goudsmith [4] carried out a detailed phylogenetic analysis of all 41 parvovirus 
genomes that were known at the time. They found discrepancies in the existing 
ICTV classification of viruses within Parvovirinae, e.g. by demonstrating that 
avian parvoviruses, at the time classified as members of the Parvovirus genus, 
were evolutionarily linked to adeno-associated viruses rather than autonomous 
parvoviruses. Probably prompted by Lukashov’s and Goudsmith’s study, ICTV 
re-evaluated parvovirus taxonomy to better reflect the phylogenetical rather 
than biological characteristics of the various species. The family is currently 
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divided into two subfamilies and five genera (Figure 1) and a sixth genus, 
Partetravirus, has been proposed to accommodate the recently discovered 
PARV4 (also known as human partetravirus; [5]). The Parvovirinae subfamily 
comprises vertebrate-infecting parvoviruses, whereas members of the 
Densovirinae subfamily only infect invertebrates such as certain species of 
mosquitos, cockroaches and moths [6]. 
 The reader is warned that one of the genera in the subfamily 
Parvovirinae, genus Parvovirus, often creates confusion of taxonomical terms, 
because the English name “parvovirus” is used commonly (and also in this 
thesis) as an umbrella term to refer to all or any individual Parvoviridae 
species. To clarify this issue, the ICTV Parvoviridae Study Group has very 
recently put forward a proposali to change the genus name to 
"Protoparvovirus". This is part of a large set of proposals by the study group to 
rationalize and extend the taxonomy of the Parvoviridae family. It is therefore 
likely that parvovirus taxonomy will undergo major changes in the near future. 
 
 
Figure 1. Taxonomy of the Parvoviridae family according to [5]. The type species of 
each genus in the Parvovirinae family is shown as an example. Genera that include 
human viruses are shown lowermost and have been shaded with grey. Genera under 
insect-infecting Densovirinae are not shown. 
The focus of this thesis, the recently discovered human bocaviruses, belong 
putatively to the genus Bocavirus. The genus derived its name from the only two 
present members, bovine parvovirus and canine minute virus, discovered in 
1961 [7] and 1970 [8]. At least 8 new putative members of the genus Bocavirus 
                                                
i The taxonomic proposals have been submitted for peer review. The version currently pending 
ICTV's internal review can be found with the DOI code 10.6070/H45X26VR. 
Family
Parvoviridae
Subfamily
Parvovirinae
infect vertebrates
Subfamily
Densovirinae
infect invertebrates
Genus
Parvovirus
- Minute virus of mice
Genus
Bocavirus
- Bovine parvovirus
Genus
Dependovirus
- Adeno-associated virus 2
Genus
Erythrovirus
- Human parvovirus B19
Genus
Amdovirus
- Aleutian mink disease virus
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have been reported between 2005 and 2013 in addition to the four human 
bocaviruses. They have been tentatively named gorilla bocavirus 1[9], porcine 
bocavirus[10], porcine boca-like virus[11], canine bocaviruses (number of 
species uncertain; [12]) and California sea lion bocaviruses 1-4 [13]. The 
phylogeny of these putative Bocavirus species is illustrated in Figure 2, together 
with representative examples from other Parvovirinae genera. The tree shown 
in Figure 2 has been determined based on the sequence that is most important 
for the serological aspects of this thesis, the amino acid sequence of the major 
capsid protein VP2. However, the mentioned set of ICTV Parvoviridae Study 
Group proposals includes a suggestion to use the amino acid sequence of the 
NS1 protein (described in chapter 5.2.2) as the basis of parvovirus taxonomy.  
NS1 version of the phylogenetic VP2 tree is included in Supplementary Figure 1. 
Based on the NS1 phylogeny, the Study Group is proposing the unification of 
HBoV1 and Gorilla bocavirus 1 under a single species, Primate bocaparvovirus 
1, whereas HBoV2 and HBoV4 would form another species termed Primate 
bocaparvovirus 2. 
  17 
 
Figure 2. Partial neighbor-joining tree of the Parvovirinae subfamily based on the amino 
acid sequences of the inferred major capsid protein VP2. Genus Bocavirus is shown in 
red and has been expanded to show most species within the genus, whereas only the 
type species are shown from each of the other genera. Sequences were aligned with 
Geneious 4.8.5 aligner using blosum62 cost matrix with gap open penalty of 12 and gap 
extension penalty of 3. The tree is derived from 100 bootstrap replicates and bootstrap 
values ≥70% are shown. The scale bar represents 0.2 average amino acid substitutions 
per site. GenBank accession number for each sequence is shown in Supplementary 
Table 1.  
As indicated in Figure 2, HBoV1 is phylogenetically closer to gorilla bocavirus 1 
than the other human bocaviruses. For instance, the major capsid protein VP2 
of HBoV1 has 90% amino acid identity with gorilla bocavirus whereas HBoV1 
and HBoV2-4 share ~80% amino acid identity. For comparison, the other 
human parvoviruses, B19 and PARV4, share only 21-23% VP2 amino acid 
sequence identity with HBoV1-4 (Table 1). 
Review of the literature 
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Table 1. Pairwise comparison of VP2 amino acid identities (%) of selected Bocavirus 
species. GenBank accession numbers for the sequences are listed in Supplementary 
Table 1. 
 HBoV1 HBoV2 HBoV3 HBoV4 
HBoV1 - 78 78 80 
HBoV2 78 - 89 89 
HBoV3 78 89 - 89 
HBoV4 80 89 89 - 
Bovine parvovirus 47 40 42 45 
Canine minute virus 46 44 44 45 
Gorilla bocavirus 1 86 80 80 80 
B19 23 21 23 21 
PARV4 22 23 24 24 
 
5.1.3 PATHOGENICITY OF ANIMAL BOCAVIRUSES 
Introduction. Gene sequence analysis enables us to compare the hypothesized 
pathogenic profile of the novel HBoVs to those of previously characterized 
parvoviruses. An HBoV profile that was similar to previously characterized 
members of the genus bocavirus could be considered with slightly less 
skepticism than a completely dissimilar pathogenic profile. Amino acid 
sequences of the capsid proteins provide a good basis for comparing 
pathogenicity in this manner since (through interaction with target cell 
receptors) they are among key determinants of tissue tropism. One could also 
compare HBoVs to parvoviruses that gain access to host cells via the same 
receptors. However, HBoV receptors are currently unknown. 
 Based on the sequences of the VP2 proteins that make up most of 
the parvovirus capsids, the closest relative to human bocaviruses is gorilla 
bocavirus 1. However, virtually nothing is currently known about this virus. 
Porcine bocaviruses and the California sea lion bocaviruses are also largely 
uncharacterized. However, the two founding members of the genus Bocavirus, 
bovine parvovirus and the canine minute virus (also known as canine parvovirus 
type-1), have been known since the 60's and the pathological properties of both 
viruses have been studied in experimental animal models. These animal 
experiments provide an opportunity to assess the outcomes and pathogenic 
mechanisms of bocavirus infections in details that would be infeasible with 
human subjects.  
  19 
 
Experimental canine minute virus infections. Carmichael and colleagues 
inoculated 21 pathogen-free and seronegative, <1-week-old pups oronasally with 
the canine minute virus and followed histological and clinical course of the 
infections [14]. Six of the 21 pups (32%) showed clinical signs of illness during 
the follow-up period. Two of these developed severe illness, one case with fatal 
outcome. Main symptom among the symptomatic individuals was respiratory 
distress. Pathological signs included inflammation of the supportive tissue 
between the alveoli, manifesting as diffuse accumulation of liquid or pus in the 
alveoli and adjoining ducts (lung consolidation; Figure 3).  
 
 
Figure 3. Macroscopic appearance of lung from a seriously ill pup, infected 
experimentally with the canine minute virus (postinoculation day 6). Lung consolidation 
is apparent in all lobes and visible as dark areas in the image. Reproduced from [14] 
with permission. Copyright SAGE Publications 1994. 
Viral titers in the pups were examined in several tissue types. The median 
TCID50ii titer of the lung tissue specimens was the highest (5×104), followed in 
descending order by the median titers of small intestines (3×103), lymph nodes 
(3×103), spleens (<5×101) and thymi (<5×101). All these tissue types were 
positive in the necropsied pups. The highest lung titers were noted in the two 
pups that developed the worst symptoms (≥ 106). The virus was not isolated 
                                                
ii TCID50 or "tissue culture infective dose" is a measure of infectious virus titer. It refers to the 
endpoint titer of the virus-containing specimen required to cause cytopathic effect or lysis in 50% of 
inoculated tissue culture cells. 
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from any of the 4 noninfected control pups or from the brain, kidney, liver, 
heart muscle or bone marrow samples of the infected pups. 
Histologic findings in the small intestine were minimal. Only scattered 
cells in the intestinal glands and villi tested positive for viral antigen by 
immunofluorescence as opposed to the strong staining of alveolar and bronchial 
epithelium. Disruption of the normal architecture of the villi was not reported. 
Authors noted the occurrence of viremia and fecal virus shedding between days 
2-8 but did not specify the number of pups testing positive in serum or feces.  
 In another study, the same authors [15] studied the pathogenicity 
of the canine minute virus for fetuses by inoculating oronasally 7 seronegative 
bitches between gestational days 25-35. Five of the 7 showed viremia that, 
according to virus cultures, lasted 1 to 3 days post-infection but none had 
clinical illness. All dogs seroconverted to the virus within 2 weeks PI. Three of 
the 7 bitches lost all fetuses within two weeks from inoculation by embryo 
resorption and one gave birth to sick pups that all died soon after birth. Three 
gave birth to healthy pups. Thirteen more fetuses in three additional bitches 
were inoculated via the amniotic sac between gestational days 35-44. All these 
fetuses died within 2 weeks from inoculation. Viral titers were measured in 
amniotic fluid, placenta, lung, heart, thymus and the final portion of the small 
intestine (ileum). The highest titers among all infected fetuses were observed in 
the lungs and ileum. As with the older pups, the lung titers of the newborn dogs 
were consistently at least 10 times higher than those of other measured tissues. 
 
Experimental bovine parvovirus infections. In one of the most detailed 
studies on experimental bovine parvovirus infections, Durham and Johnson 
[16] inoculated 15 calves that had been kept in isolation until maternal 
antibodies against the virus had been reduced to low or non-detectable levels. 
Six of the calves were inoculated orally, four were not inoculated but were left in 
contact with the inoculated individuals and five animals were retained as 
isolated controls. The inoculated calves developed mild to moderate diarrhea, 
fever and reduced leucocyte counts within two or three days from inoculation. 
The in-contact controls also developed diarrhea, whereas the uninoculated 
control calves remained asymptomatic. Microscopic study of the small 
intestines revealed significant damage to the villi and intestinal glands only 32 
hours after infection, as illustrated in Figure 4.  
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Figure 4. Scanning electron micrographs of the ileal mucosa of two calves; (A) healthy 
control, (B) 32 hours after infection with the bovine parvovirus. Bars represent 400 µm. 
Adapted from [16], with permission. Copyright Elsevier 1985. 
Inspection of sequential necropsy tissues by immunofluorescence microscopy 
indicated that tonsillar tissues, intestinal mucosa and to a minor degree 
mesenteric lymph nodes all became infected with bovine parvovirus within 32 
hours from inoculation. Most prominent fluorescence was reported in the 
glandular epithelia of the small intestine. These tissues remained positive after 3 
days, at which point a relatively large number of fluorescent cells were also 
observed in the thymus. After 5 days from inoculation, only the final section of 
the small intestine (ileum) and thymus remained positive in 
immunofluorescence microscopy. Tonsil, the portions of small intestine 
preceding ileum (duodenum & jejunum), colon, spleen and all tested lymph 
nodes were negative at this point. No fluorescent cells were seen in liver, lung, 
kidney, heart or testes at any time point. 
 In a similar experiment, Storz and colleagues [17] studied bovine 
parvovirus infection in orally inoculated calves and reported organ distribution 
and symptoms that were very similar to those described above. In another 
experimental infection, Spahn and colleagues [18] did not carry out histological 
analyses but noted that orally inoculated calves developed only diarrhea, while 
those inoculated intranasally also developed a mild respiratory illness in the 
form of nasal discharge. In contrast to the mostly asymptomatic canine minute 
virus infections in pups (see previous subchapter), all four studies reported mild 
to moderate diarrhea in all inoculated calves. 
 
Principal target cells. It is easy to see why parvoviruses would target the 
intestinal mucosa. The cells that cover this surface are very short-lived and are 
continuously replaced by new cells. Parvoviruses are generally believed to 
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require these kinds of rapidly dividing cells or helper viruses for efficient 
replication because their minute genome does not carry sufficient genetic 
information to code for their own replicative enzymes [3,6,19]. Studies also have 
yet to show that parvoviruses could force the host cell into S-phase of 
replication. 
 The most vigorously replicating cells in the small intestine are 
located in intestinal glands, also known as Crypts of Lieberkühn, which produce 
the epithelial cells of the villi. The basal portion of the crypt contains 
multipotent stem cells. After each mitosis, one of the two daughter cells 
migrates up to the side of the crypt and eventually into the villus while the other 
remains in the crypt as stem cell [20]. The study by Durham and Johnson 
supported the notion that bovine parvovirus specifically infect the intestinal 
glands by showing how the infected cells sequentially moved from the base of 
the intestinal glands towards the tips of the villi. By disabling the new source of 
cells, the virus can prevent dying cells on the villi from being replaced. This 
results in significantly reduced absorption capacity of the intestines, leading to 
diarrhea and nausea. Even death can result if the intestinal barrier is sufficiently 
reduced to allow intestinal bacteria to gain access to the bloodstream. 
  Unlike the rapidly dividing cells of the small intestine, the lung 
epithelial cells are considered to have a relatively slow renewal rate at least 
among adults [21]. It is therefore surprising that infection by the minute virus of 
canines typically results in significantly higher viral titers in the lungs than in 
other organs. In the already discussed experimental infection of dogs, 
Carmichael and colleagues [14] demonstrated that the two seriously ill pups had 
at least 1000 fold higher viral titers in the lung than in the organ with the next 
highest viral titer, the small intestine. 
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5.2 HUMAN BOCAVIRUSES 
5.2.1 DISCOVERY 
The famous Louis Pasteur quote, "chance favors the prepared mind in 
the field of observation", applies well to the discovery of the first two human 
parvoviruses. The adeno-associated virus, was observed visually when Atchison 
and colleagues [22] were inspecting the purity of an adenovirus preparation 
with an electron microscope. The second human parvovirus, parvovirus B19, 
was found in a similar manner when researchers used an electron microscope to 
investigate a serum that gave anomalous results in immunoassays [23]. 
However, chance was a minor factor in the discovery of the first human 
bocavirus, HBoV1, by Allander and colleagues [24], and their finding is better 
described by another aphorism, "success follows excellence". 
 The discovery was made with a pioneering screening method, also 
developed by Allander and colleagues [25], which was specifically designed to 
discover new viruses from human specimens. The method involved the 
following five phases: 1) enzymatic and mechanical host DNA depletion to 
enrich viral nucleic acids, 2) amplification of enriched DNA by random PCR, 3) 
cloning of the PCR products, 4) large-scale sequencing of the clones, and 5) 
automated editing and database searches of the sequencing results. HBoV1 was 
found when the screening method was applied on respiratory samples obtained 
from the patients with a suspected respiratory infection [24]. The virus was 
identified from DNA clones that did not match any known viruses at the 
nucleotide level, while simultaneously showing significant similarity to the 
amino acid sequences of the bovine parvovirus and the canine minute virus. 
The concept of random PCR screening was quickly adopted by other 
researchers, thus widening the systematic exploration of as yet unknown human 
viruses. This resulted in the discoveries of HBoV2 [26], -3 [26] and -4 [27] in 
2009 and 2010. Unlike HBoV1, however, all these three viruses were found in 
human fecal samples rather than respiratory specimens. 
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5.2.2 GENOME 
The small ~5 kb genome encodes three major separate open reading frames as 
illustrated in Figure 5.  The 5' region encodes the NS1 protein, which appears to 
be involved in the regulation of HBoV promoter activity [28]. The middle region 
of the genome encodes the nucleoprotein 1 (NP1), which has an unknown 
function, and the 3' region encodes the two structural proteins VP1 and VP2. 
The structural proteins are formed from the same transcript using alternative 
splicing. As a result, VP1 and VP2 differ only in their N-terminal region and the 
unique portion of VP1 is known as VP1u. 
 Studies published so far indicate that human bocaviruses may 
differ from other parvoviruses with respect to their genome structures and 
replication mechanisms. Typical parvovirus genomes are considered single-
stranded DNA molecules that consist a relatively long single stranded coding 
sequence bracketed by short imperfect terminal palindromes that fold back onto 
themselves to form hairpin structures [3], as illustrated in Figure 5. The 3' end 
of the hairpin functions as a primer to initiate replication of the viral genome 
from the left-terminal sequence in a so called rolling-hairpin manner [29]. In 
contrast, recent data indicates that human bocavirus genomes can exist and/or 
persist as closed circular DNA molecules [30,31]. Figure 5 illustrates the 
genomic organization of human bocaviruses in the form of an HBoV3 episome 
that was discovered from an intestinal biopsy [31]. A similar HBoV2 episome 
was recently reported in the fecal specimen of a diarrheic Chinese child [32]. 
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Figure 5. Schematic representation of A) a typical parvovirus genome organization in 
the hairpin configuration and B) the suggested HBoV episomal configuration with 
HBoV3 genome as an example. The arrow in image A represents the direction of DNA 
replication. Image B is based on the GenBank sequence JN086998 and the protein 
encoding sequences are based on data from [33] and [34] . Encoded proteins are 
indicated as arrows and the thin line in the NS1 arrow symbolizes an intron gap.  See 
the text for description of each encoded protein. 
Sequence analysis of HBoV genome sequences has indicated that their evolution 
has involved interspecies recombination events. Kapoor and colleagues [27] 
compared the regional sequence similarities of human bocaviruses and found 
that the NS1 and NP1 genes of HBoV3 cluster with those of HBoV1 whereas at 
the other side of the genome, VP1/2 genes cluster with those of HBoV2. HBoV4, 
on the other hand, is more similar to HBoV2 in NS1/NP1 but with HBoV3 in 
VP1/2. In one possible chain of events, HBoV3 may have originated from a 
recombination event between HBoV1 and HBoV2, whereas HBoV4 may have 
originated from recombination between HBoV3 and HBoV2. 
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5.2.3 STRUCTURE 
The human bocavirus genome is protected by a non-enveloped capsid that, 
based on native HBoV1 particles, has a diameter of approximately 28 nm [35]. 
The absence of a lipid envelope and the simple overall structure make 
parvovirus capsids exceptionally resilient to environmental challenges. Bovine 
parvovirus particles can withstand 100°C dry heat for 30 minutes with one log 
reduction in infectivity, whereas typical pasteurization protocol for human 
serum albumin (3 h at 60 degrees with moist heat) would reduce bovine 
parvovirus infectivity by three logs [36].  
 Similar to other parvoviruses, HBoV1 [37] and HBoV2-4 (B. 
Gurda, personal communication) capsids are icosahedral and consist of 60 
copies of structural proteins. Based on studies on human parvovirus B19, VP2 
units make up ~95% of the capsid in native particles [38]. The VP2 protein has 
highly conserved secondary structure core elements that are shared even 
between parvovirus genera while the variable surface loops confer the host-
specific tropism and the diverse antigenic properties [37]. The remaining ~5% of 
the capsid structure consists of minor proteins, the type of which depends on 
the virus species. All contain low numbers of VP1 molecules but some species, 
for example minute virus of mice and porcine parvovirus, also contain VP3, 
which is formed from VP2 by proteolytic cleavage [3]. Some HBoV1 VP2 
molecules also appear to be cleaved to form VP3 [35]. 
 The VP2 monomers of several (and possibly all) parvovirus species 
can self-assemble into virus-like particles (VLPs) in the absence of other 
proteins. The production of recombinant VP2 VLPs in insect cells has been 
demonstrated e.g. for parvovirus B19 [39,40], canine parvovirus type 2 [41], 
feline panleukopenia virus [41], Aleutian mink disease parvovirus [42] and 
indeed for HBoV1-4 as discussed in the results section of this thesis. All the 
referenced studies have reported that the recombinant VP2 capsids appear to be 
similar to native capsids in appearance and, when measured, in buoyant 
density. The VP2 capsids have also been successfully used in the serodiagnosis 
of parvovirus infections (e.g. [43-46]), indicating that also the antigenic 
properties of the artificial capsids resemble those of the native capsids. 
 The ability of VP2 monomers to self-assemble into VLPs does not 
mean that VP1 is dispensable for productive infection. A study on the minute 
virus of mice (MVM) first demonstrated that virus that lacks VP1 binds to cells 
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as efficiently as wild-type virus but fails to initiate a productive infection. The 
requirement for VP1 is thought to be important for endosomal escape [47,48] 
and nuclear targeting [49]. In the case of parvovirus B19, it appears to be also 
essential for efficient internalization of the virus [50]. 
5.2.4 HBoV1 EPIDEMIOLOGY 
Respiratory samples. The discovery of HBoV1 in children with respiratory 
disease rapidly prompted a large number of confirmatory studies assessing the 
presence of the virus in respiratory specimens. Since these are routinely taken 
from symptomatic individuals but only rarely from asymptomatic individuals, 
most studies have focused on HBoV1 prevalence among the former. Results 
from studies assessing the incidence of HBoV1 DNA in the respiratory samples 
of patients with respiratory disease are summarized in Table 2. The list of 
studies was adapted from a 2012 systematic review by Jartti and colleagues [51]. 
Some studies were excluded based on criteria that are detailed in the table's 
footnote. It is evident from the tables that HBoV1 infections occur commonly 
around the globe and are mainly detected in young children aged 6-24 months. 
In contrast, detection of HBoV1 in the respiratory specimens of 
immunocompetent adults is rare.  Data are scarce on the occurrence of HBoV1 
infection among the elderly. 
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Table 2. Age-stratifieda HBoV1 DNA prevalences in patients with respiratory disease as 
measured by PCR from respiratory specimens 
Study 	   Age	  (years) Country %	  
positive 
n Symptoms 
[52] NPS <1 Thailand 10 67 pneumonia 
[53] NPA median 0.7 
range 0.1 - 4.9 
Korea 0 212 ALRTI 
[54] NPA median 1.2 
range 0.1 - 5.8 
Korea  8 336 ALRTI 
[55] NPA median 1.3 Canada 14 225 ARTI 
[56] NPA median 1.6 
range 0.3-15 
Finland 19 259 AEW 
[57] nasal swab <2 USA 33b 106 "respiratory 
illness" 
[52] NPS 1-4 Thailand 12 302 pneumonia 
[58] NPA mean 3.4 y Germany 10 835 ARTI 
[59] NPS <5 Vietnam 2 958 ARTI 
[60] NPA <5 France 4 589 ARTI 
[61] mixedc <6 Canada 3 290 ARTI 
[61] mixedc 6-15 Canada 2 149 ARTI 
[52] NPS 5-19 Thailand 3 132 pneumonia 
[52] NPS 20-49 Thailand 1 213 pneumonia 
[61] mixedc 16-50 Canada 1 444 ARTI 
[55] NPA >40 y Canada 1 126 COPD 
[52] NPS 50-64 Thailand 1 149 pneumonia 
[61] mixedc >50 Canada 0.3 149 ARTI 
[52] NPA >65 Thailand 1 305 pneumonia 
ALRTI, acute lower respiratory tract infection; ARTI, acute respiratory tract infection; AEW, acute 
expiratory wheezing; COPD, chronic obstructive pulmonary disease; n, number of subjects; NPS, 
nasopharyngeal swab; NPA, nasopharyngeal aspirate 
aThe studies have been arranged by age and studies with multiple age groups [52,61] have been split to 
separate rows with one age group per row.  
bMultiple samples were obtained from each individual, increasing the likelihood of virus detection. 
Other studies analyzed one respiratory sample per study subject. 
cSpecimen types analyzed included throat swabs, nasopharyngeal swabs, nasopharyngeal aspirates and 
auger suctions. 
Note: The list of studies is based on a previous systematic review [51]. Studies were excluded from the 
table if detection was based on a novel PCR method and the results were not verified by sequencing or 
by another independent assay [62-65]. Also studies with ambiguous descriptions of ages [66] or 
symptoms [67,68] were excluded. 
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Several studies have demonstrated the detection of HBoV1 DNA in the 
respiratory samples of completely asymptomatic individuals and individuals 
with non-respiratory symptoms. However, before inspecting these data and 
comparing it to data on symptomatic individuals, there are several important 
factors that need to be considered:  
 
1) PCR has been used only in a few studies to analyze respiratory samples of 
truly asymptomatic patients. Several studies have designated subjects as 
"control patients" or "asymptomatic control patients", although they may have 
experienced other than respiratory symptoms [52], or taken part in elective 
surgery [55,69,70]. A frequently performed elective surgery is tonsillectomy, 
which may correlate positively with HBoV1 infection by direct causal 
relationship or enhancement of HBoV replication e.g. by recruitment of immune 
cells permissive for HBoV1 infection (discussed in [71]). 
 
2) Presence of HBoV1 DNA in respiratory samples does not necessarily indicate 
an acute infection, and by extension, does not by itself demonstrate a subclinical 
infection in an asymptomatic individual. This has been shown in several studies 
on immunocompetent children, documenting extended or intermittent HBoV 
persistence in the respiratory tract. For instance, a Danish prospective birth 
cohort study found that 25% of 228 young immunocompetent children 
remained PCR positive at least 2 months after the appearance of HBoV1 DNA in 
respiratory specimens [65], whereas a Finnish study of otitis-prone children 
found that 11% of 152 children were HBoV1 DNA positive after 3 months  and 
one child after 6 months [72]. At least two other studies [57,73] have also 
reported the prolonged or intermittent presence of HBoV1 DNA in respiratory 
specimens of immunocompetent children.  
 
3) Studies on completely asymptomatic individuals are scarce and the numbers 
of participants in these few studies are typically small because respiratory 
samples are not routinely collected from asymptomatic individuals. The small 
number of individuals increases the likelihood of all subjects showing a negative 
result. 
 
4) The procedure commonly used for respiratory specimen collection from 
symptomatic individuals is a painful and unpleasant nasopharyngeal swab or 
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aspiration (Figure 6), whereas truly asymptomatic individuals have been almost 
exclusively sampled with significantly less invasive nasal swabs. This difference 
in sampling procedures would favor the detection of HBoV1 DNA in 
symptomatic individuals if HBoV1 (or its DNA) preferentially persisted in the 
nasopharynx or lower parts of the respiratory tracts. Swabs also provide 
significantly lower volumes of mucous sample material for DNA extraction than 
aspirates, potentially reducing the likelihood of HBoV1 DNA detection. This 
difference in detection sensitivities has been previously demonstrated with 
other viruses. Chan and colleagues [74] measured RSV and influenza viral load 
in nasopharyngeal aspirates and nasopharyngeal flocked swabs (NPFS) 
obtained in parallel from 196 hospitalized children with acute respiratory 
infection and found that, on average, NPA samples yielded 9 times higher RSV 
and 33 times higher influenza A DNA levels than NPFS samples. Also, 
Heikkinen and colleagues [75] found that 97% of patients with RSV tested 
positive in NPA by PCR as opposed to 76% in swab samples (RSV positivity was 
based on total viral findings by either method). Differences in detection 
sensitivities between these two methods have not been determined for HBoV, 
but they are likely to be significant in patients with low viral loads. On the other 
hand, the increased likelihood of HBoV1 DNA detection in the nasopharyngeal 
samples of symptomatic patients could be counterbalanced by the greater 
exposure of the nasal swab sampling area to exogenous ("contaminating") 
sources of HBoV1 DNA.   
 
 
Figure 6. Nasopharyngeal swabs and aspirates are sampled from the uppermost part of 
the throat, i.e. the nasopharynx, by passing the sampling instrument through a nostril. 
Image copyright was licensed from 123RF Ltd (Hong Kong, China). 
Keeping the above issues in mind, Table 3 lists studies that have assessed the 
prevalence of HBoV1 in patients without any symptoms or without symptoms 
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indicative of a respiratory infection. The list of studies has again been adapted 
from the systematic review of Jartti and colleagues [51] and complemented with 
another study [76]. 
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Table 3. Age-stratifieda HBoV1 DNA prevalences in the respiratory samples or stool 
samples of patients without respiratory or gastrointestinal disease 
Study Sample 
type 
Enrollment 
criteria 
Age 
(years) 
Country % 
positive 
n 
[65] nasal swab asymptomatic <1 Denmark 9 152 
[57] nasal swab asymptomatic <2 USA 44 45 
[68] nasal wash asymptomatic <2 USA 0 96 
[77] saliva asymptomatic 2-4 USA 9 56 
[70] NPA elective surgery AVG 3.6 
RNG not 
specified 
Norway 17 162 
[52] NPS outpatient clinic, 
no ARD 
<4 Thailand 5 85 
[69] NPA trauma,       
elective surgery, 
well-child visit 
<5 France 0 68 
[76] NPS asymptomatic <5 China 3 195 
[55] NPA elective surgery "children" Canada 43b 100 
[78] NPA elective surgery, 
food challenge 
"children" Spain 5 116 
[52] NPS outpatient clinic, 
no ARD 
5-19 Thailand 0 69 
[52] NPS outpatient clinic, 
no ARD 
20-49 Thailand 0 54 
[52] NPS outpatient clinic, 
no ARD 
>50 Thailand 1 72 
[79] stool asymptomatic <5 Korea 4 115 
[26] stool asymptomatic median 1.8 
RNG 0.1-17 
Australia 6 186 
NPS, nasopharyngeal swab; NPA, nasopharyngeal aspirate; ARD, acute respiratory disease; AVG, 
average; RNG, range. 
aThe studies have been arranged by the age of the patients and a study with multiple age groups [52] 
was split to separate rows with one age group per row.  
bThese children were hospitalized for a surgery (mostly ear, nose or throat surgeries) but did not have 
respiratory symptoms. Results were verified by two independent quantitative PCRs as well as 
sequencing. 
Note: a study with very small number of subjects (<50; [80]) was excluded from the table. 
  Interestingly, the two highest HBoV1 DNA prevalences ever 
published have been among individuals without respiratory symptoms. Martin 
and colleagues [57] performed HBoV testing on nasal swabs in a prospective, 
longitudinal study of respiratory illness in 119 children who attended daycare, 
and documented HBoV in 20 of 45 (44%) of asymptomatic enrollment samples. 
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Longtin and colleagues tested nasopharyngeal aspirates and found HBoV DNA 
in 43 of 100 (43%) of children undergoing elective surgery (mostly ear, nose and 
throat surgeries) without concomitant respiratory symptoms or fever at 
admission [55]. 
 Because of the complicating factors discussed above, it is 
impossible to assess potential correlation, let alone causal relationship, between 
HBoV1 infection and respiratory symptoms by comparing Tables 2 and 3. 
Chapter 5.2.6 addresses correlations and causalities by looking at individual 
studies in more detail. However, these two tables give us rough approximations 
of the prevalences of HBoV1 DNA in symptomatic and asymptomatic 
individuals and show us that the mere presence of HBoV1 DNA in respiratory 
specimens is not a reliable indicator of a symptomatic respiratory infection. A 
significantly better sign of an acute infection is likely to be the presence of a high 
viral load in respiratory specimens or the presence of viral DNA in blood (i.e. 
viremia). Allander and colleagues found that 88% of children with more than 
104 copies/ml of HBoV1 DNA in NPA had viremia as opposed to only 11% of 
children in whom the copy number was <104 copies/ml of starting sample [56]. 
The significance of viremia as a marker of an acute HBoV1 infection is discussed 
in more detail in the results section of this thesis (chapter 8.6). 
 
Non-respiratory samples. HBoV1 does not appear to show the same type of 
tissue persistence that characterizes human parvovirus B19. After primary 
infection, the B19 DNA may remain detectable in the tissues of both 
symptomatic and asymptomatic subjects for several decades. Persistence of B19 
DNA has been reported in synovial membranes (i.e the tissue covering the 
inside surface of most joint cavities), skin and tonsils with detection frequencies 
of 16-50% [81,82]. B19 DNA is also frequently found in heart tissue, with one 
study reporting a DNA prevalence of 85% in 100 patients who underwent open-
heart surgery [83].  In contrast, no evidence of HBoV1 DNA persistence has 
been found in the tonsils of adults or in the skin or synovial tissues of any age 
group [84]. Only tonsils of young children aged <8 years tested positive for 
HBoV1 [84] and none the tonsils, synovial membranes or skin tested positive for 
HBoV2-4 regardless of age. Of the 100 heart patients who were mostly positive 
for B19 DNA [83], only 5% tested positive for HBoV1 DNA. 
 Schildren and colleagues [85] tested tissue specimens from lung 
and colorectal cancers for HBoV1 DNA and found 18% of the lung tumors and 21 
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of the colorectal tumors positive for the virus. HBoV1 DNA has also been found 
in stool and urine. Pozo and colleagues analyzed urine samples from six 
hospitalized LRTI patients and found HBoV1 DNA in two of the children [86], 
which appears to be the only published study on the subject. The virus DNA has 
also been found in stools of children with gastrointestinal or respiratory illness. 
Among these types of children aged <6 years, the range of DNA detection has 
been 0.5-9% in major studies with at least 300 patients [79,87-91]. Average 
detection frequency appears to be ~4%. The presence of HBoV1 DNA in stool 
and urine may well be indicative of swallowed virus or virus filtrated from the 
blood in the kidneys, rather than active shedding in either secretory pathway. 
Passive spread of HBoV1 from the respiratory to the gastrointestinal tract is 
supported by the consistently low levels of viral DNA in stool [92]. 
 HBoV1 DNA detection in the stools of adults is rare. The most 
comprehensive study on the subject analyzed ~2300 samples from individuals 
with gastrointestinal disease and ~2100 asymptomatic controls [93]. The ages 
of the patients and controls ranged from <1 to >70 years with relatively even age 
distribution in different age subgroups (1-4 y, 5-9 y, 10-19 y, 20-29 y etc). None 
of the adults tested positive for HBoV1 DNA in contrast to 2% of children aged 
<4 years. 
 The ability of parvovirus B19 and the canine minute virus (an 
animal bocavirus; chapter 5.1.3) to cause intrauterine infection and abortion has 
prompted research into the possible role of HBoV1 in fetal disease. However, no 
HBoV1 DNA was found in 87 amniotic fluid specimens from fetuses with 
hydrops, anemia or isolated effusions [94]. Another study examined fetal tissues 
(placenta, heart and liver) from 120 miscarriages and 169 intrauterine fetal 
deaths and found that no HBoV1 DNA [95].  
5.2.5 HBoV2-4 EPIDEMIOLOGY 
Respiratory samples. Human bocaviruses show significant similarity on 
amino acid and nucleotide level but appear to differ significantly in tissue 
tropism. As discussed, HBoV1 is seen mainly as a respiratory virus and the 
presence of HBoV1 DNA in stool specimens may reflect swallowing rather than 
gastrointestinal shedding. In contrast, HBoV2-4 are considered enteric viruses 
because they are mainly detected in stool and only rarely in respiratory 
specimens. This is reflected by a comprehensive study by Chieochansin and 
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colleagues [67], involving ~6200 respiratory samples from Scotland and ~400 
from India. The ages and symptoms of these patients were not specified but the 
sample type (mainly NPA) indicates respiratory symptoms. None of the 
respiratory specimens tested positive for HBoV2 whereas HBoV1 was found in 
3% of the Scottish and 14% of the Indian samples.  However, the Scottish 
samples were pooled from 10 individual samples, inevitably resulting in reduced 
DNA detection sensitivity.  
 Later studies have demonstrated that HBoV2-4 are not entirely 
absent from respiratory specimens. Chinese [96], Korean [53] and Japanese 
[97] studies have respectively reported HBoV2 in 4%, 2%  and 0.5% of (non-
pooled) respiratory specimens from children with respiratory tract disease. Of 
these three, the Japanese study was the only one also to test the samples for 
HBoV3 and -4 DNA. Detection rates for both viruses were ~0.5%. In Finland, 
Risku and colleagues screened ~1500 nasal swabs from children with acute 
respiratory tract disease and found HBoV1-4 respectively in 4.5%, 0.2%, 0% and 
0% of the samples (M. Risku, submitted). Thus, the incidence of HBoV2-4 in 
respiratory samples is low in comparison to HBoV1. None of these studies 
assessed the quantity of HBoV2-4 DNA in the respiratory specimens, since all 
were based on qualitative PCRs. However, the HBoV2 loads in respiratory 
specimens are likely to be low considering their complete absence in the 
aforementioned >6000 pooled English respiratory samples [67].  
 In the absence of quantitative data showing moderate or high 
respiratory DNA loads, the mere presence of HBoV2-4 DNA could indicate 
contamination of respiratory airways by viral DNA from fecal material rather 
than active shedding. Future studies should address this possibility by testing 
for HBoV2-4 mRNA rather than DNA as successfully shown for HBoV1 [98].  
 
Stool samples. It is difficult to summarize the age-related incidence of HBoV2 
DNA in stool samples in any great detail because most studies have focused on 
samples from wide age groups and/or provided inadequate information about 
the age distribution of the study subjects. Table 4 summarizes results from 
studies that have assessed the occurrence of HBoV2 in symptomatic and 
asymptomatic individuals. 
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Table 4. Age-stratifieda HBoV2 prevalences in the stool of symptomatic and 
asymptomatic individuals 
Study age	  (years) Country %	  positive n Symptom
s 
[99] median 1.5 
range 0-16 
Korea 4 358 GE 
[100] mean 1.7 
range 0-1.7 
China 20 632 GE 
[26] median 1.7 
range 0-18 
Australia 17 186 GE 
[27] median ND 
range 0-15 
Nigeria            
Tunisia 
23 192 NPAFP 
[101] "children" China 25 345 GE 
[27] "adults" 
 
USA 4 87 GE 
[27] "adults" 
 
Nepal 4 96 GE 
[102] median ND 
range 0-15 
Finland 3 878 GE 
[100] mean 0.9 
range 0-1.7 
China 12 162 healthy 
[26] median 1.8 
range 0-17 
Australia 8 186 healthy 
[27] median ND 
range 0-15 
Tunisia 24 96 healthy 
[27] "adults" 
 
USA 0 74 healthy 
[27] "adults" 
 
Nepal 4 96 healthy 
ND, not disclosed; GE, gastroenteritis; NPAFP, non-polio acute flaccid paralysis. 
aThe studies have been arranged by age and studies with multiple age groups have been split to separate 
rows with one age group per row. 
Note: studies that had very wide age groups and did not report average or median ages [103,104] were 
excluded from the table. Results from the study by Risku and colleagues [102] were partially excluded 
due to very few individuals (<50) in some patient groups. A wavy line separates results from 
symptomatic and asymptomatic subjects. 
HBoV2 prevalence appears to be relatively high among young children and low 
in adults based on the few studies that do have reasonably narrow age groups. 
This resembles the occurrence of HBoV1 in respiratory samples. Also 
reminiscent of HBoV1 is the occurrence of HBoV2 DNA in the stool of 
asymptomatic children. In fact, the second highest reported HBoV2 prevalence 
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(24%; highest 25% [101]) has been reported in the stool of 96 asymptomatic 
Tunisian children [27]. 
 HBoV3 DNA occurs less frequently in stool than HBoV2 DNA but 
may exceed the occurrence of HBoV1 DNA. A Finnish study of ~900 children 
with gastroenteritis found HBoV1-4 DNA with respective frequencies of 6%, 3% 
and 1% [102]. An even more comprehensive English study of ~2000 
gastroenteritis patients found HBoV1-3 DNA with respective frequencies of 3%, 
22% and 7% [93]. 
 HBoV4 DNA detection appears to be rare in stool specimens in 
comparison to HBoV1-3, with only two studies reporting the presence of any 
HBoV4 positive results; one study found the virus in 2% of Tunisian children 
with acute flaccid paralysis (2%; [27]) and the other in 0.5% of Thai children 
with gastroenteritis. Three other studies, however, did not find any HBoV4 DNA 
in stool [102,105,106]. 
5.2.6 HBoV1-4 CLINICAL SIGNIFICANCE 
Criteria for establishing causality. Koch's postulates are three widely cited 
criteria designed to assess a causal relationship between a causative microbe 
and a disease. Different translations and interpretations of the original criteria 
exist, but according to Fredericks and Relman [107] they are:  
 
1. The pathogen occurs in every case of the disease in question and under 
circumstances, which can account for the pathological changes and clinical 
course of the disease 
2. The pathogen occurs in no other disease as a fortuitous and nonpathogenic 
parasite 
3. After being fully isolated from the body and repeatedly grown in pure 
culture, the pathogen can induce the disease anew. 
 
It is easy to see how these three postulates, suggested in the 19th century before 
knowledge of viral diseases, do not have to be fulfilled to reasonably establish a 
pathogen as the cause of a disease. The first postulate does not apply to a large 
number of pathogens that cause non-unique symptoms, such as respiratory 
infection or gastroenteritis. The second postulate is difficult to fulfill for several 
reasons, not least because a pathogen's ability to cause disease can vary widely 
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depending on the host's genetic makeup. The third postulate has been 
unreasonable for pathogens that can potentially cause severe disease and which 
do not have good animal models (e.g. mumps virus). Experimental bocavirus 
infections in consenting adults would probably not be dangerous but they would 
not necessarily represent the effects of primary infection in young children. 
However, the spirit of Koch's rules still holds in that scientists must 
demonstrate that a virus is not only associated with a disease but that it is 
actually the cause.  
 Several revisions to the original Koch's postulates have been 
proposed and among the most recent are the "molecular guidelines for 
establishing microbial disease causation" [107]. The guidelines are listed with 
Arabic numerals below and discussed to see how well the existing HBoV 
measures up with the criteria. Some of the lengthy original 7 guidelines have 
been split into smaller elements for the sake of clarity whereas others have been 
pooled together with minor text editing.  
 
Rule 1) "A nucleic acid sequence belonging to a putative pathogen should be 
present in most cases of an infectious disease".  
 
As mentioned, it is not reasonable to expect HBoV DNA in most cases of 
respiratory or gastrointestinal disease because a wide variety of human 
pathogens, both eukaryotic and viral, result in these symptoms. Most 
researchers have instead tried to investigate whether HBoV DNA is more often 
present in symptomatic than asymptomatic individuals but the results are often 
difficult to interpret because of differences in sampling techniques, the lack of 
truly asymptomatic controls and the prolonged shedding of HBoV1 (and 
possibly HBoV2-4) in the respiratory and fecal specimens.  
 We can nevertheless try to inspect epidemiological data from the 
studies in which the aforementioned confounding factors have been minimized. 
The focus of this inspection is on the presence or absence of viral nucleic acids 
in asymptomatic and symptomatic individuals. HBoV copy numbers are also 
mentioned to avoid repetition of data, but the importance of viral loads will be 
discussed in more detail later in the chapter. 
 To the present author's knowledge, only two studies have 
compared the occurrence of HBoV1 in children with and without respiratory 
disease and fulfilled five important criteria: i) the control cases were truly 
  39 
asymptomatic and not e.g. undergoing elective surgery ii) the same sampling 
technique was used for both cohorts, iii) the samples were collected within the 
same time period, iv) the age distributions of the two groups were similar and v) 
the samples were collected from the same geographical area.  
 The first study by Linstow and colleagues was a prospective birth 
cohort study, which followed initially healthy infants for 1 year [65]. All children 
were from the same birth cohort ensuring identical age distribution, sampling 
technique, geography and time among symptomatic and asymptomatic children. 
Information on respiratory symptoms was collected from daily diaries to 
minimize the risk of recall bias. The presence of HBoV was determined with 
monthly nasal swabs. The authors found HBoV1 DNA in 8.2% of nasal swabs 
from symptomatic children with acute respiratory tract infection and in 8.6% of 
samples from asymptomatic children. The mean viral load in symptomatic 
individuals was 4-fold higher than in asymptomatic individuals without 
reaching statistical significance. However, the absence of statistical significance 
is difficult to assess without an estimate of statistical power. Symptoms in 
HBoV1 positive children without known coinfection with other respiratory 
viruses were generally mild, most commonly nasal discharge (90%) or cough 
(70%). 
 The second well-controlled investigation to meet all five 
aforementioned inclusion criteria was also a prospective cohort study [57], 
involving young children attending daycare. HBoV1 was reported in 44% of 45 
asymptomatic children and 34% of 41 symptomatic children. The virus load in 
both groups was the same (within margin of error), 4.9×104 copies/ml among 
symptomatic and 4.6×104 copies among asymptomatic patients. HBoV infection 
alone was not associated with onset of illness and viral load did not correlate 
with severity of illness.  
 Unlike these two prospective studies, a study by Christensen and 
colleagues compared children with signs of RTI (median age 17 mo) to control 
children admitted for elective surgery (median age 31 mo). Even though the 
control children were not truly asymptomatic and their median age was almost 
twice the age of the RTI group, the study is highly relevant for this discussion. 
This is because Christensen and colleagues used HBoV1 mRNA rather than DNA 
as a marker of ongoing infection and both subject groups comprised entirely of 
subjects with HBoV1 DNA in NPA. The authors found that HBoV1 mRNA was 
detected in nasopharyngeal aspirates from 33 (25%) of 133 children with RTI 
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but in none of the 28 controls undergoing elective surgery. The authors also 
found that among all HBoV1 positive children, NPA DNA loads were 
significantly higher in children positive for HBoV1 mRNA in NPA than negative 
children (Figure 7). Both results were statistically very significant. 
 
 
Figure 7. Distribution of HBoV1 DNA loads in nasopharyngeal aspirates either positive 
(n=33) or negative (n=128) for HBoV1 mRNA. Each dot indicates one sample. Digitally 
recreated from Figure 3 in [98] with adaptations. 
Two studies assessing the roles of human bocaviruses in gastrointestinal disease 
also meet the five inclusion criteria. An Australian study [26] tested fecal 
samples from ~190 case-control pairs for HBoV1-3 DNA with qualitative PCR 
and found a significant association (17% vs. 8%) between HBoV2 detection and 
acute gastroenteritis (AGE). HBoV1 was not statistically associated with AGE 
(9% vs. 6%) and the number of HBoV3 positive samples was not high enough 
for meaningful conclusions. An English study analyzed ~2000 cases with 
gastroenteritis and an equal number of healthy controls [93] and found that  
HBoV2 was associated with gastroenteritis (1.4% vs. 0.8%) across children and 
adults. However, in children aged <5 years the prevalences in cases and controls 
were similar, 2.8% and 2.6%, respectively. HBoV3 occurred at ~1% frequency in 
the controls and patients aged <5 years and was not associated with 
gastroenteritis.  
 With slightly more relaxed inclusion criteria (different sampling 
intervals for cases and controls) the results of two other studies can also be 
inspected.  Chen and colleagues [79] analyzed stools from ~400 cases and ~120 
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controls for HBoV1 DNA and found no difference in HBoV1 DNA positivity 
(3.5% vs. 3.5%). In the other study, Jin and colleagues [100] reported a 
statistically significant association between HBoV2 and gastroenteritis  (20% vs. 
12%). Both studies used quantitative PCR for virus detection but neither found 
statistically significant difference in DNA loads between cases and controls.  
 Statistically meaningful data are currently not available on the 
association of HBoV4 with human disease, since the virus was found so recently 
and occurs very rarely in respiratory or fecal specimens. 
 
Rules 2 and 3) "Microbial nucleic acids should be found preferentially in those 
organs or gross anatomic sites known to be diseased (i.e., with anatomic, 
histologic, chemical, or clinical evidence of pathology) and not in those organs 
that lack pathology. Tissue-sequence correlates should be sought at the cellular 
level: efforts should be made to demonstrate specific in situ hybridization of 
microbial sequence to areas of tissue pathology and to visible microorganisms 
or to areas where microorganisms are presumed to be located". 
 
Of the human specimen types studied so far (respiratory, urinary, fecal and 
tissue) HBoV1 DNA is undoubtedly most frequently found in respiratory 
specimens. Currently there is no histologic in vivo evidence for or against 
pathogenicity, as this would require lung or colorectal biopsies. However, the 
effects of HBoV1 infection have been studied in vitro using cultured 
pseudostratified human airway epithelium, the sole cell type currently known to 
support HBoV1 propagation. The first such study reported only slight 
morphological stretching of the cells [33]. There was no disruption of the cell 
layer, changes in cell density, ciliary movement or mucosal secretion compared 
to non-infected cells. However, the examination was done only 4 days after 
infection. A later and more thorough study continued observing the cells for up 
to 3 weeks post-infection and documented significant histological alterations 
starting approximately on day 7 post-infection [108]. These alterations included 
disruption of cell-to-cell tight junctions and loss of cilia. The tight junctions are 
likely to be the most important determinant of forming a virtually impermeable 
barrier to fluid, whereas cilia are important for the removal of mucus and 
exogenous particles from the respiratory airways. Compromise of these factors 
in vivo would contribute to the buildup of fluid and mucus in the lungs, the 
prominent features of pulmonary infiltrates and lung consolidation. There are 
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no published in vitro studies on the potential histological effects of HBoV2-4 
infection.  
 
Rule 4) "The nature of the microorganism inferred from the available sequence 
should be consistent with the known biological characteristics of that group of 
organisms".  
 
The phylogenetically closest relatives of human bocaviruses that have been 
pathogenetically characterized are the canine minute virus and the bovine 
parvovirus. As we have seen in chapter 5.1.3, these viruses can cause respiratory 
or gastrointestinal disease, which is in line with the hypothesized roles of HBoV1 
and HBoV2-4 in human disease. However, the implications of these roles should 
not be overestimated, since the human and animal bocaviruses are 
phylogenetically not very closely related (40% VP2 amino acid identity). We 
have already seen how remarkably the tissue tropism of HBoV1 and HBoV2-4 
appear to differ despite sharing ~80% VP2 amino acid identity (chapters 5.2.4 
and 5.2.5).  
 In contrast to the tentative supporting link in respiratory and 
gastrointestinal disease, the known biological characteristics of parvoviruses 
form a significant body of evidence against a causal link between HBoVs and 
cancer formation. The notion that HBoV1 infection could promote human 
cancer was recently put forward by Schildgen and colleagues [85] who found 
HBoV1 DNA in ~20% of colorectal and lung cancer tissues. The authors did 
acknowledge that actively replicating tumor cells could provide an optimal 
environment for HBoV1 since parvoviruses are believed to prefer dividing and 
proliferating cells. However, it should have also have been noted that 
parvoviruses are generally considered to suppress rather than promote tumor 
development.  This oncosuppressive effect of parvoviruses has been 
demonstrated in laboratory animals (reviewed in [109]). Parvoviruses were 
found to protect the animals e.g. from chemically induced tumors, to suppress 
the development of established tumors and to make the animals less susceptible 
to tumor grafts. The tumor-suppressive effects are believed to result from the 
oncolytic effect of parvovirus infection [3].  
 
Rules 5-7) "Fewer, or no, copy numbers of pathogen-associated nucleic acid 
sequences should occur in hosts or tissues without disease and the copy 
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number of pathogen-associated nucleic acid sequences should decrease or 
become undetectable with resolution of disease. With clinical relapse, the 
opposite should occur. When sequence detection predates disease, or sequence 
copy number correlates with severity of disease or pathology, the sequence-
disease association is more likely to be a causal relationship". 
 
The limitations of simply comparing symptomatic and asymptomatic 
individuals for the incidence of HBoV1 DNA in respiratory specimens have 
already been discussed. However, information about viral copy numbers 
expands our ability to evaluate association between infection and disease also 
beyond well-paired cohorts of healthy and diseased individuals. For example, a 
Norwegian team of scientists [70] studied HBoV DNA levels in children with 
elective surgery (controls) and children admitted to hospital due to acute 
respiratory tract infection (cases). The authors found more HBoV1 positive 
respiratory samples in the controls than among the cases, but high (>106 
copies/ml) NPA loads were strongly associated with infection of the lower 
respiratory tract. Very high levels of HBoV1 DNA in NPA (>108 copies/ml) also 
occurred exclusively among children with respiratory symptoms. On the other 
hand, the scientists who discovered HBoV1 examined children hospitalized for 
acute expiratory wheezing and found a positive association between high NPA 
DNA load and the absence of coinfecting respiratory viruses [56].  
 A Chinese [76] study examined children with X-ray-diagnosed 
lower respiratory tract infection and compared the severity of symptoms to the 
level of HBoV1 DNA. The authors reported a very clear difference in DNA loads 
between patients and healthy controls, as well as betweeevern mild and severe 
symptoms. Virtually all patients had viral loads in excess of 104 copies/ml cutoff 
level whereas all healthy controls had DNA levels below this level. The DNA load 
of the nasopharyngeal swab extracts of the healthy controls was on average 
1000 fold lower than in the NPA samples from the patients. 
 HBoV1's pathogenetic role is also supported by three case reports 
that have found HBoV1 infection in children with life-threatening respiratory 
disease and adequately excluded other known viral, bacterial and fungal 
pathogens. HBoV1 DNA loads in these children were very high at the peak of 
symptoms (109 -1010 copies/ml) and decreased or became undetectable at the 
resolution of symptoms [110-112]. All three children had severe respiratory 
distress, all three showed lung infiltrates and two had abnormal collection of air 
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in the pleural space that separates the lung from the chest wall (pneumothorax). 
Chest radiograph of one of the three cases is illustrated in Figure 8.  
 
 
Figure 8. Chest radiographs of an asymptomatic individual and a 16-month-old Finnish 
boy with human bocavirus 1 pneumonia on 2nd day of hospitalization. Pulmonary 
infiltrations and atelectasis (collapse of lung tissue) of the right lobe can be seen. 
Copyright to the left side image has been licensed from 123RF Ltd (Hong Kong, China). 
Right side image reproduced from [110] with permission. 
HBoV1 coinfection rate. It is reasonable to assume that HBoV1 can cause 
respiratory disease based on the data discussed so far. However, the overall 
clinical significance of the virus in comparison to other major respiratory 
pathogens in children hospitalized for respiratory symptoms is open for 
discussion. As we have seen, prospective or follow-up studies have not 
established a role for HBoV1 in respiratory disease among non-hospitalized 
children. On the other hand, HBoV1 infections in hospitalized children appear 
to have a remarkably high coinfection rate not only according to PCR analysis of 
respiratory specimens (the usefulness of which is undermined by DNA 
persistence) but also according to serodiagnosis and viremia. By comparing data 
from two studies on a group of children hospitalized for acute expiratory 
wheezing [56,113], one can see that only 25% of serologically diagnosed acute 
HBoV1 infections were monoinfections whereas the corresponding (PCR-based) 
figures for rhinovirus and RSV (diagnosed only by PCR) were at least twice as 
high, 77% and 50%. Equally high co-infection rate was noted by the Norwegian 
study on children admitted to hospital for respiratory tract infection. Of 18 
children with HBoV1 viremia, 6 (33%) had no other respiratory virus in the 
NPA. It is therefore possible that infections by other respiratory viruses 
facilitate HBoV1 infection and therefore contribute to HBoV1's association with 
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respiratory disease. This would not be an unprecedented phenomenon, since 
influenza virus infection can mediate infection by vesicular stomatitis virus and 
Semliki Forest virus by enhancing the binding of these viruses to the respiratory 
epithelia [114]. RSV, on the other hand, is commonly detected with HBoV1 and 
can evidently suppress T-cell responses to itself and other antigens [115].  
 
Summary.  Existing data are in line with the notion that HBoV1 infections 
among immunocompetent individuals mostly result in mild symptoms (or are 
subclinical) but can sometimes cause serious symptoms requiring 
hospitalization. Well-controlled studies indicate an association between HBoV2 
and gastroenteritis but causality has not been established. Not enough is 
currently known about HBoV3 or HBoV4 for a meaningful assessment of their 
role in human disease. 
5.3 ORIGINAL ANTIGENIC SIN 
5.3.1 INTRODUCTION 
Based on research done on influenza, dengue and human immunodeficiency 
viruses (and possibly others), close structural similarity between related viruses 
may give rise to a immunologic phenomenon known as original antigenic sin 
(OAS). This phenomenon has potential to significantly modify immunological 
responses against later viral infections. As demonstrated in the results of this 
thesis, antibody responses against human bocaviruses also appear to conform to 
the OAS phenomenon. OAS does not only have the potential to influence the 
body's subsequent capability to stave off infections but also complicate their 
serological diagnosis. To paraphrase a recent editorial on OAS [116]: "what is 
original antigenic sin, what is its immunologic basis, and what sort of trouble is 
it getting us?" 
Epidemiologist Thomas Francis, Jr (1900-1969) was a prolific 
vaccine researcher and the first to isolate influenza virus in the USA. While 
studying immune responses to influenza viruses, Francis and colleagues noted 
that sequential exposure to closely related influenza virus variants appeared to 
yield an antibody response that was significantly influenced by the first stimulus 
even if spaced several years apart. In one of the first and perhaps most 
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illustrative studies on the phenomenon [117], the effect of antibody absorptioniii 
on hemagglutination inhibition (HAI) was studied with pre-vaccination serum 
pools from three different age cohorts; adults (30+ y), military recruits (17-25 y) 
and children (4-10 y). Each serum pool was separately absorbed with three 
different influenza strains; SW derived from the 1918 epidemic, PR8 isolated in 
1934 and FM1 from the 1947 epidemic. The SW strain matched the type of 
strains circulating in the childhood of the adult cohort whereas PR8- and FM1-
like strains had circulated in the childhood of the military recruits and children, 
respectively. The most interesting results were observed when absorption of the 
adult serum pool with the childhood SW strain also removed HAI activity 
against the PR8 and FM1 strains even though the adults had by necessity been 
exposed to these types of viruses after their early years. In contrast, HAI activity 
against the childhood SW strain was mostly retained in these individuals when 
the same serum pool was pre-absorbed with the later PR8 and FM1 strains. 
Similar results were observed from the vaccination of children with the SW and 
PR8 strains, since HAI activity towards both vaccines was entirely removed by 
absorbing the sera with the childhood FM1 strain. As with the adult subjects, 
activity toward the childhood FM1 strain was mostly retained after absorption 
with SW or PR8 strains.  
To confirm their results, the authors carried out consecutive 
infections of ferrets with different unattenuated influenza strains. Results from 
one such infection experiment are illustrated in Figure 9. The ferret was first 
infected with SW strain, 7 months later with a Weiss strain, and further 6 weeks 
later with a CAM strain. Serum was collected from the animal 2 weeks after each 
infection. When the final serum was absorbed with the strain of the first 
infection (SW), all HAI-active antibodies against all three strains were removed. 
In contrast, absorption with the second and third infecting strains only removed 
a relatively small proportion of the HAI activity of the first strain. Based on 
these and other similar results the authors concluded that exposure of the 
“virgin” ferret to the first infecting strain somehow prevented the formation of 
specific antibodies against the later two strains.  
 
                                                
iii The process of removing or "tying up" undesired antibodies in an antiserum by allowing them to 
react with their antigens 
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Figure 9. Hemagglutination-inhibition titers of ferret sera with and without antibody 
absorption after successive infections with 3 live strains of influenza H1N1 virus. In the 
upper image, the solid black bars represent the measured titer levels without antibody 
absorption. In the lower image, the black outlines show the same pre-absorption titers 
for visual reference, whereas the solid black bars represent the post-absorption titers. 
Digitally recreated from Figure 5 in study [117] (with adaptations). 
Francis and colleagues also studied the effects of repeated homologous 
immunizations on children that grew up during the circulation of FM1-like 
influenza strains. The children were given 3 doses of monovalent vaccines 
containing Cuppet (isolated in 1950's), SW, PR8, or FM1 virus and the immune 
responses were measured without antibody absorption. As illustrated in Table 5, 
the secondary strains yielded highest antibody titers against the FM1 strain at 
the apparent expense of weaker responses to their own epitopes. Repeated 
exposures did not override the governing effect of the primary strain. 
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Table 5. HAI antibody titers in pools of sera obtained before and after administration of 
monovalent vaccines to children aged 4 to 10, born during the circulation of an FM1-like 
influenza strain. All titers were measured without antibody absorption. Adapted from 
[118]. 
Group Vaccine Bleeding 
HAI titer with test strain 
SW PR8 FM1 Cuppet 
1 
SW 1 0 0 256 32 
SW 2 1024 128 >16384 1024 
SW 3 1024 64 >16384 1024 
- 4 2048 32 >16384 2048 
2 
PR8 1 0 0 1024 64 
PR8 2 64 2048 2048 128 
PR8 3 64 2048 2048 128 
- 4 64 1024 2048 128 
3 
FM1 1 0 0 256 32 
FM1 2 0 0 4096 512 
FM1 3 0 32 4096 512 
- 4 0 32 4096 512 
4 
Cuppet 1 0 0 256 32 
Cuppet 2 32 128 4096 1024 
Cuppet 3 0 64 8192 1024 
- 4 0 64 8192 512 
 
 
In 1960 Francis wrote a commentary [119] in which he reflected the data 
collected during the last decade and termed the new phenomenon: 
 
“The antibody of childhood is largely a response to the dominant antigen of the 
virus causing the first Type A influenza infection of the lifetime. As the group 
grows older and subsequent infections take place, antibodies to additional 
families of virus are acquired. But the striking feature is that the antibody, 
which is first established, continues to characterize that cohort of the 
population throughout its life. The antibody-forming mechanisms have been 
highly conditioned by the first stimulus so that later infections with strains of 
the same type successively enhance the original antibody to maintain it at the 
highest level at all times in that age group. The imprint established by the 
original virus infection governs the antibody response thereafter. This we have 
called the doctrine of original antigenic sin.” 
 
It is interesting that Francis' own description of OAS was rather vague and 
specifically highlighted the enhancement of antibodies against the first antigen 
rather than the lack of antibodies toward the second antigen.  
Indeed, the concept of OAS appears to be rather elusive since some authors 
invoke it unnecessarily. For instance, a recent letter to the journal of Emerging 
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Infectious Diseases [120] discussed the recent H1N1 pandemic and drew 
attention to the fact that young individuals were at greater risk from acquiring 
H1N1 infection than older individuals. The authors suggested possible 
involvement of OAS in protecting the elderly [120]. The ensuing editorial 
commentary [116] asked whether OAS could be "an epidemiologic blessing in 
disguise". It is not clear why one would invoke OAS instead of simply immune 
memory to explain the age distribution of the H1N1 pandemic. On the other 
hand, one study reported mere heterologous boosting as evidence of OAS while, 
paradoxically, demonstrating robust activation of naïve B cells against the 
secondary antigen [121]. Needless to say, the heterologous boosting can be 
explained by stimulation of immune memory by shared epitopes between the 
primary and secondary antigen without any need to invoke a new phenomenon. 
Other studies have reported in support of OAS that, following the second 
immunization of primed animals, antibody or neutralizing titer against the 
secondary antigen was lower than against the primary antigen [122,123]. Direct 
comparison of titers after the second immunization overlooks the fact that 
secondary immunizations build upon existing immunological memory against 
the primary antigen, which can most likely be stimulated not only by identical 
epitopes but also by epitopes that are sufficiently similar between the two 
antigens. To clarify this issue, Figure 10 illustrates hypothetical antibody 
responses against consecutive immunizations with related antigens. As can be 
seen in the left side of the image, consecutive antibody responses can be 
expected to result in a lower overall antibody titer against the secondary antigen 
even in the absence of OAS. However, humoral response against the secondary 
agent would still yield an antibody response that is equal to that generated 
against the primary agent with respect to the titer of antigen-specific antibodies. 
Thus, a more reasonable comparison between the primary and secondary 
immune responses should be made by comparing the titer of specific antibodies 
against the primary antigen with the titer of specific antibodies against the 
secondary antigen. 
 For OAS to deserve its own term, it should be defined in a way that 
somehow distinguishes it from a typical immune memory response. In this 
thesis, the term is used to denote the inhibited activation of naïve B or T cellsiv 
                                                
iv A naive B or T cell refers to a cell that has not been exposed to an antigen. Upon antigen exposure, 
it proliferates into many clones. Some of the clones are transformed into effector cells that will defend 
the body in an immune response whereas others are transformed into long-lasting memory cells.  
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toward a secondary antigen due to pre-existing immunity toward a previously 
encountered primary antigen.  
 
Figure 10. Hypothesized antibody responses to consecutive immunizations with two 
related antigens in the absence and presence of original antigenic sin. Black and blue 
symbols represent antibodies produced by the activation of naïve B cells against the 
primary and secondary antigens, respectively. Green symbols represent antibodies 
produced by the activation of memory B cells (from the 1st infection) by the secondary 
antigen. The large number of green circles relative to the number of hexagonal symbols 
symbolizes the ability of the fully matching epitopes to stimulate memory B cell 
receptors with higher efficiency than partially matching epitopes. Note: OAS is 
demonstrated here as complete inhibition of naïve B cell activation but the real 
phenomenon probably gives rise to a spectrum of inhibition depending on 
immunological circumstances. 
5.3.2 POTENTIAL MECHANISMS OF INDUCTION AND EVASION 
One possible mechanism for the formation of OAS is the inhibition of naïve B 
cell recruitment through the action of Fcγ receptors.  Fcγ receptor is a protein 
found on the surface of certain cell types the immune system, such as B and T 
lymphocytes, macrophages and neutrophils. Its name is derived from its 
binding for the constant region (Fc) of IgG molecules. There are different types 
of Fc receptors, each binding to different class of antibodies. The Greek letter γ 
indicates that Fcγ receptor specifically binds to IgG. As illustrated in Figure 11, 
Fcγ receptors may inhibit naïve B cell activation because the co-engagement of 
the Fcγ receptors and the B cell receptors (BCR) by antigen-IgG complexes 
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blocks the activation signal from the BCR [124-126]. Although not shown 
experimentally, at least four other mechanisms could also take part in the 
suppression of primary immune responses: (1) masking of new epitopes by the 
binding of antibodies to closely located conserved epitopes, (2) competition for 
antigen by higher affinity memory cells, (3) annihilation of antigen by 
phagocytotic cells or the complement system before it can reach the naïve B-
cells in sufficient quantity and/or (4) limitation of the propagation of the 
secondary pathogen so that less antigen is available for the stimulation of the 
immune system. This last potential mechanism, the limited availability of 
antigen, may be brought by B or T cells targeting conserved (and in the case of B 
cells, neutralizing) epitopes in the secondary antigen. Thus, based on points 2 
and 4, OAS may be partially mediated by cross-immunity.  
 
Figure 11. Inhibition of naïve B-cell activation by cross-linking of B-cell receptors and  
Fcγ  receptors. Copyrights to reproduced image elements (viral capsid, antibody 
molecule and the receptor molecule) have been licensed from 123RF Ltd (Hong Kong, 
China). 
All these possible mechanisms of OAS could potentially be evaded by increasing 
the load of the secondary antigen sufficiently to “flood” the inhibitory 
mechanisms. This could have a significant effect on the results obtained from 
immunization experiments and cause discrepant results with native infections, 
in which the antigen loads are several orders of magnitude smaller. Large 
antigen doses could play some role in a recent study [127] that called into 
question the significance or perhaps even existence of OAS. The authors used 
vaccinated human volunteers to isolate human immunoglobulin variable 
regions from individual antibody-secreting plasma cells to study the affinity of 
monoclonal antibodies against different strains of influenza. Even though all 
volunteers had been vaccinated against other influenza strains prior to 2007, 
most of the mAbs showed highest affinity toward the 2007 vaccine strain, 
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indicating efficient naïve B cell activation. Based on these results, the authors 
suggested that OAS does not seem to be a common occurrence in healthy adults 
receiving influenza vaccinations. 
 In addition to sufficiently low antigen loads, it is also possible that 
manifestation of OAS on the B and T cell level somehow requires live virus 
infections rather than immunizations with an inactivated virus. This was 
suggested by Kim and colleagues [128], who studied the effects of OAS in mice 
by vaccinating the animals with whole inactivated influenza viruses or 
sequentially infected with live mouse-adapted viruses. They found no firm 
evidence of OAS in the sequentially vaccinated mice in terms of serum 
neutralization titer or HAI activity, but profound OAS induction in the 
sequentially infected mice was detected. Secondary infection of PR8-primed 
mice with the FM1 strain of influenza A resulted in neutralization and HAI titers 
against FM1 ten-fold lower than in primary infection of non-primed mice.  
5.3.3 CLINICAL SIGNIFICANCE 
The clinical implications of OAS are easy to understand, since inhibition of 
activation of naïve lymphocytes may allow the secondary virus to escape 
neutralizing immune responses. A relatively recent study illustrated the 
practical effects of OAS. In this study mice were sequentially immunized with 
sublethal doses of live influenza PR8 and FM1 strains (in this order) and then 
giving them a lethal dose of FM1 [128]. To compare the results to a "regular 
immunization", they used mice that first received PBS, then a sublethal dose of 
live FM1, and finally a lethal dose of FM1. Non-vaccinated controls first received 
two sequential doses of PBS and then a lethal dose of FM1. The results are 
illustrated in Figure 12.  
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Figure 12. Induction of original sin in mice by sequential infection with 0.1×LD50 of PR8 
and FM1 viruses (LD50 is the dose required to kill half the members of a test population). 
The mice were first infected with PR8 (or treated similarly with phosphate buffered 
saline [PBS]) and the first follow-up sample was taken 28 days later (d28; image A). The 
mice were then infected with FM1. Follow-up samples were collected on days 7, 14 and 
28 and analyzed for neutralization titers (image A; error bars represent the standard 
error of the mean). After the last follow-up sample, the mice were challenged again with 
FM1 but this time with a lethal dose (FM1; 100×LD50). A few days after the lethal dose, 
the lungs of the mice were harvested and assessed for FM1 titers (image B). Bracketed 
numbers indicate the number of mice with no detectable FM1 in lungs. Each data point 
represents an individual animal. Error bars represent standard error of the mean. 
Adapted from [128] with permission (copyright 2009, The American Association of 
Immunologists, Inc).  
As shown in the Figure, the naïve, unimmunized control mice that received only 
PBS exhibited lung titers of 107 plaque-forming units (pfu) per ml upon the final 
FM1 challenge, whereas the mice that were first immunized with sublethal dose 
of FM1 cleared the virus completely. In contrast, the mice that had sequentially 
received a sublethal dose of PR8 and FM1 developed lung titers of 104 pfu/ml. 
The results demonstrate that FM1 immunization among PR8-primed mice left 
the animals vulnerable to later FM1 infection, whereas FM1 immunization of 
"virgin" mice resulted in complete protection. However, one should note that 
the primed mice were partially protected against the infection and not worse off 
than the virgin animals with respect to the ensuing viral titers.  
 Antibody-dependent enhancement of infection (ADE) may be one 
mechanism of the clinical effects of OAS. According to ADE, non-neutralizing 
IgG molecules bound to virus particles promote infection of Fc-bearing cells 
such as monocytes and macrophages through endocytosis (Figure 13). OAS may 
mediate ADE by inhibiting the formation of neutralizing antibodies against the 
second infecting virus strain, especially if the neutralizing antibodies are mostly 
directed toward non-conserved epitopes that require the activation of naïve B 
cells. This would give rise to a pool of antibodies which mainly serve to enhance 
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viral access into Fc-bearing cells without obstructing the spread of the virus. 
ADE was first suggested by R. A. Hawkes who showed that virus-specific 
antisera were able to increase the infectivity of certain arboviruses in cell 
cultures [129]. A later study with a dengue virus showed that the infection-
enhancing factor was an IgG-class antibody. In-vitro ADE by sub-neutralizing 
IgG has also been demonstrated for Aleutian mink disease parvovirus [130] and 
several influenza A subtypes [131]. 
 
 
Figure 13. Model for antibody-dependent enhancement (ADE) of dengue virus 
replication [132]. Reprinted in adapted format by permission from Macmillan Publishers 
Ltd: Nature, copyright 2007. 
ADE has been hypothesized to be partially responsible for the increased risk of 
life-threatening dengue haemorrhagic fever/dengue shock syndrome in 
secondary dengue virus infections [133]. This potentially fatal disease is 
characterized by increased vascular permeability leading to hemoconcentration 
and hypovolemic shock. The clinical significance of ADE has been demonstrated 
in a mouse model [134]. Passive administration of anti-dengue antibodies to the 
mice enhanced dengue virus infection and gave rise to several hallmarks of 
severe dengue disease, including vascular leakage, reduction of blood platelets 
and increased viral loads in serum and tissue phagocytes. In contrast, 
genetically engineered monoclonal antibodies that could no longer bind FcγR 
had preventive and therapeutic efficacy against a dengue virus challenge. 
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6 AIMS OF THE STUDY 
When this thesis project was initiated, HBoV1 was the only human bocavirus 
known and the diagnosis of HBoV1 infections relied on PCR analysis of 
respiratory or serum specimens. Moreover, nothing was known about HBoV 
immunity. The initial aim of the study was therefore 
 
1) To study HBoV1-specific B-cell responses and assess their diagnostic use 
in young children with respiratory disease. 
 
The subsequent discovery of HBoV2-4 introduced three new human bocaviruses 
that were phylogenetically closely related to HBoV1 and to each other. The 
immunological properties of HBoV2-4 and the potential cross-reactivity of anti-
HBoV antibodies in serological tests were unknown.  Furthermore, the detection 
of these viruses relied on nested PCR assays, which are laborious and 
inappropriate for accurate quantitation of viral DNA. The other aims of the 
study were therefore 
 
2) To develop and evaluate real-time quantitative PCR assays for the 
detection of HBoV1-4 DNA 
 
3) To develop antibody assays for the study of HBoV1-4 immune responses 
 
4) To assess the cross-reactivity of HBoV1-4 in serological assays 
 
5) To assess the extent of HBoV1-4 circulation in Finnish children and 
adults 
 
6) To determine the longevities of IgG and IgM responses against the four 
HBoVs 
 
7) To study the immunological interactions of consecutive HBoV1-4 
infections 
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7 MATERIALS AND METHODS 
7.1 SUBJECTS 
7.1.1 ADULTS AND CHILDREN WITH DIARRHEA (I) 
Stool samples were collected from 250 Finnish children or adults with 
symptoms of diarrhea [135]. Of the 250 individuals, 100 had travelled outside 
Northern Europe within 1 month prior to sample acquisition. The median ages 
of the travellers and non-travellers were 31 years (range <1 to 74 years) and 53 
years (range <1 to 95 years), respectively. The travel destinations were Europe 
(54%), Asia (29%), Africa (9%), South America (2%) or unknown (2%). Of all 
subjects, 33 were children aged 0 to 10 years, of whom 12 (36%) had travelled 
abroad. The samples were submitted to a diagnostic laboratory for routine 
testing and provided to us without identifying information. 
7.1.2 CHILDREN WITH ACUTE WHEEZING (II, III) 
The study cohort consisted of children with acute expiratory wheezing [136]. At 
hospital admission, a nasopharyngeal aspirate (NPA) was collected [136]. Blood 
samples were collected at the time of admission and 2–3 weeks after discharge. 
The NPA samples of the entire cohort of 259 children have been 
analyzed in an earlier virus etiology study [56] for the following 16 viruses: 
HBoV1; adenovirus; coronaviruses 229E, OC43, NL63 and HKU1; 
enteroviruses, rhinoviruses, influenza viruses A and B,  human 
metapneumovirus, parainfluenza viruses 1-4 and respiratory syncytial virus. Of 
these 259 children, 49 were HBoV1 PCR positive in NPA. 
Paired serum samples from 252 of the 259 children were available for 
this thesis project. For Study II, we included all the 49 children with HBoV1 
DNA in NPA and, as controls, 68 randomly selected children without HBoV1 
DNA in NPA. For Study III we included all 252 children. The demography of 
both subpopulations and the entire cohort of 252 children are illustrated in 
Table 6. The Ethics Committees of Turku University Hospital (Turku, Finland) 
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and Helsinki University Hospital (Helsinki, Finland) approved the study 
protocol. 
Table 6. Demography of the children with acute wheezing. 
 No of patients Median age Age range 
 
All children; Study III 252 1.6 y 2 mo - 15 y 
HBoV1 NPA PCR positive 
subset; Study II 
49 2.2 y 5 mo – 11 y 
HBoV1 NPA PCR 
negative subset; Study II 
68 2.5 y 5 mo – 12 y 
 
7.1.3 FINNISH MEDICAL STUDENTS AND PAKISTANI BLOOD 
DONORS (III) 
Serum samples were obtained from 115 healthy Finnish medical students 
(median age 23 years; range 21–32 years) [113,137] and 80 Pakistani blood 
donors (median age 20 years; range 18– 20 years). Written informed consent 
was obtained from the study participants. 
7.1.4 "DIPP" CHILDREN WITH GENETIC SUSCEPTIBILITY TO 
TYPE 1 DIABETES (IV) 
The study population consisted 109 constitutionally healthy children from 
whom serum samples (n=1961) were obtained with 3- to 6-month intervals from 
infancy to up to 13 years of age. The children were participants in a population-
based Diabetes Prediction and Prevention (DIPP) study and were genetically 
susceptible to type 1 diabetes [138]. These children have been previously 
examined from infancy up to adolescence by HBoV1 immunoglobulin (Ig)M, 
IgG, and IgG-avidity enzyme immunoassays and quantitative PCR (qPCR) [139].  
 Of the entire set of 1961 serum samples, 1943 were available for 
this thesis project. The available samples were reanalyzed for HBoV1 antibodies 
and analyzed for the first time for HBoV2-4 antibodies and DNA. The patient 
demographic and sampling parameters are summarized in Table 7. The ethics 
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committee of the Hospital District of Southwest Finland approved the study 
protocol.  
Table 7. DIPP cohort demography and sampling. 
 Median Mean Range 
No of samples 17 18 17-27 
Age at the beginning of sampling 0.3 y 0.3 y 0.2 y – 0.9 y 
Age at end of sampling 8.5 y 8.0 y 4.0 – 13.2 y 
Sampling interval when age < 2 y 96 d 110 d 55 - 484 d 
Sampling interval when age ≥ 2 y 182 d 197 d 92 - 849 d 
 
7.2 HBoV1-4 MULTIPLEX qPCR ASSAY (I) 
Assay principle. There are two main types of qPCR assays: those based on 
DNA binding agents and those based on Förster (or fluorescence) resonance 
energy transfer (FRET). The former can be problematic because the dyes bind to 
any double-stranded DNA in the reaction, including primer-dimers and other 
non-specific reaction products, potentially resulting in false positive results and 
overestimation of the target concentration. FRET-based methodology offers 
better assay specificity since a positive result requires the specific binding of at 
least three oligonucleotides. The oligonucleotides furthermore have to bind the 
same target molecule with sufficient affinity, be in correct orientation relative to 
one another and spaced sufficiently close for a positive signal to be generated. 
Different variations of the FRET-based methodology exist but the assay in this 
thesis was based on the "hydrolysis probe" approach that is illustrated in Figure 
14. 
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Figure 14. Principle of hydrolysis probe based DNA quantitation. The quenching moiety 
prevents emission of fluorescent light by the fluorophore in an intact probe molecule by 
converting incoming radiomagnetic radiation into heat or another wavelength that is not 
registered by the detector. However, the fluorophore is released from the quencher's 
influence when the polymerase reaches the annealed probe and degrades it by 
catalyzing phosphodiester bond hydrolysis. Each round of amplification increases the 
amount of probe template and therefore the amount of fluorescence through the build-
up of the non-suppressed reporter molecules. 
Plasmid controls. Development of qPCR assays for HBoV1-4 DNA detection 
required plasmid constructs containing at least partial virus genomes for use as 
amplification templates. For this purpose we selected parts of the left-hand 
untranslated region and the NS1 gene of the human bocavirus genomes, 
corresponding in HBoV1 to nucleotides (nt) 98 to 388 (GenBank accession 
number EU984245). The HBoV2 and HBoV3 sequences corresponding to the 
GeneBank entries FJ170279 and EU918736, respectively, were synthesized by 
GenScript corporation (NJ, USA). The HBoV4 sequence corresponding to the 
GenBank entry FJ973561 was synthesized by PCR with two long overlapping 
primers as template (Figure 15 & Table 8) and cloned into pJet1.2 (Fermentas, 
Burlington, Canada) by standard cloning practices. A near-full-length HBoV1 
clone (pST2; GenBank accession no DQ000496) was a kind gift from Tobias 
Allander (Karolinska Institute, Sweden). PCR specificity was evaluated with 
cloned full-length of near-full-length genomes of parvovirus B19 genotypes 1-3 
(GenBank accession numbers AY504945.1, AY044266 & NC_004295.1), Torque 
teno virus (AY666122.2), BK virus (DQ305492) and JC virus (AB372036). 
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Figure 15. Synthesis of the HBoV4 insert by assembly PCR. 
Primers and hydrolysis probe. The intra- and interspecies variation of 
human bocavirus genomes was studied by aligning nine HBoV1 sequences, nine 
HBoV2 sequences, four HBoV3 sequences, and one HBoV4 sequence. The 
HBoV1 and -2 strains were selected from a wide variety of geographical 
locations (10 countries). For HBoV3 and -4, we used all near-full-length 
genomic sequences that were available in 2010. The GenBank accession 
numbers and geographical origins of these sequences have been listed in 
Supplementary Table 3. 
The sequence analysis revealed a genome region that was fully 
conserved among all known bocavirus species and strains (Figure 16). A DNA 
probe conjugated with minor groove binder (MGB), 5’ FAM fluorophore and 3’ 
black hole quencher 1 (BHQ1) targeted this region. The flanking (non-
conserved) DNA regions in turn were targeted with five primers. 
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Figure 16. DNA sequence alignment of the HBoV1 to -4 genome segments used for the 
qPCR. The alignment has been split into two parts as indicated by the arrow. 
Intraspecies sequence variation is underlined and shown as degenerate bases 
according to the symbols of the International Union of Pure and Applied Chemistry 
(IUPAC; R = A+G; Y = C+T). Fully conserved nucleotides are shown without 
underlining, whereas nucleotide differences between the species are in bold. Annotated 
(blue and brown) arrow symbols show the positions and directions of the primers and 
the probe. For HBoV2 and HBoV4, direct PCR product identification is possible by PCR 
product sequencing to distinguish the three-nucleotide difference. 
In multiplex format the conserved probe together with the five primers were 
designed to detect all published types of human bocaviruses. In a singleplex 
format, the same primers could be used in pairs to distinguish between HBoV1, 
HBoV3 and HBoV2/4. The primer and probe sequences are listed in Table 8. 
The primer names indicate their usage. For instance, primer HBoV234F is the 
forward (sense) primer shared by HBoV2, -3 and -4 qPCRs while the HBoV1R 
reverse (antisense) primer is only applicable to HBoV1 PCR. 
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Table 8. Primers used for the development of HBoV1-4 qPCR multiplex assay. 
Name Sequence (5'->3') 
HBoV1F CCTATATAAGCTGCTGCACTTCCTG 
HBoV1R AAGCCATAGTAGACTCACCACAAG 
HBoV234F GCACTTCCGCATYTCGTCAG 
HBoV3R GTGGATTGAAAGCCATAATTTGA 
HBoV24R AGCAGAAAAGGCCATAGTGTCA 
Probe FAM-CCAGAGATGTTCACTCGCCG-MGB 
HBoV4, synthetic F GCACTTCCGCATCTCGTCAGACTGCATCCGGTCT 
CCGGCGAGTGAACATCTCTGGAAAGAGCT 
HBoV4, synthetic R GAGCAGAAAAGGCCATAGTGTCACTCACCACAA 
GCGTGGAGCTCTTTCCAGAGATGTTCACT 
HBoV4F GCACTTCCGCATCTCGT 
HBoV4R CACTATGGCCTTTTCTGCTC 
 
The HBoV2 and HBoV4 primer binding sites in the HBoV2 and HBoV4 
plasmids are identical except for a single-nucleotide difference in the forward 
primer (Figure 16). Moreover, in silico secondary-structure predictions with 
Mfold [140] showed no major difference between the amplified regions of the 
two sequences (data not shown). This minor difference was taken into account 
by using a degenerate nucleotide. Preliminary experiments indicated that the 
two plasmids were indistinguishable with respect to assay sensitivity and 
reproducibility. Consequently, the results reported in the results of this thesis 
(chapter 8.1) for HBoV2 and HBoV4 are designated “HBoV2/4” and were 
acquired with the HBoV2 plasmid. 
 
Real-time PCR and sequencing. All quantitative PCRs were done using 
Stratagene Mx3005p qPCR device (Stratagene, CA). The reactions consisted of 
1x TaqMan Universal Master Mix (Applied Biosystems, CA) with AmpErase 
uracil-N-glycosylasev (UNG), 0.6 µM concentrations of primers, 0.3 µM FAM-
labeled probe and 2 µl of template in 25 µl total volume. Only one primer pair 
was used in singleplex reactions whereas the multiplex reaction included all five 
primers. 
UNG was allowed to degrade potential carryover PCR products for 2 
min at 50°C. After further 10 min at 94°C, 40 cycles of amplification (95°C for 
                                                
v Uracil N-glycosylase (UNG) is an enzyme used for the elimination of carryover PCR products. The 
dUTP nucleotide is substituted for the dTTP nucleotide when using this enzyme, resulting in dUTP 
containing PCR amplicons. A short pre-PCR incubation step in subsequent PCR amplifications will 
allow the UNG to digest dUTP-containing DNA.  
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15 s, 60°C for 1 min) were performed. All runs included plasmid and no-
template controls. To generate baseline-corrected fluorescence data, baseline 
fluorescence was determined by the Mx4000 software version 3.01 (Stratagene) 
baseline algorithm. The cutoff for quantification cycle determination was 
calculated as 20 times the standard deviation of the baseline fluorescence in 
cycles 5 through 9. The fluorescent reporter signal from the FAM channel was 
measured against the internal reference dye (ROX) signal to normalize for non-
PCR-related fluorescence fluctuations between samples. Rigorous laboratory 
procedures were followed to prevent PCR contamination, including separate 
spaces for handling of samples, master mix components, and plasmid 
templates. Aerosol resistant filter tips and disposable racks were used. All runs 
included water controls, which remained negative throughout the study. 
 The PCR products were enzymatically purified for sequencing 
using ExoSAP-IT (USB Corporation, Ohio, USA). Sequencing was done at the 
sequencing core facility of Haartman Institute. The sequences were compared to 
GenBank database entries with Geneious 4.5 (Biomatters Ltd, Auckland, New 
Zealand). 
7.3 HBoV VP2 EXPRESSION 
7.3.1 PROKARYOTIC HBoV1 VP2 EXPRESSION (II) 
Cloning. The entire HBoV1 VP2 and the unique region of HBoV1 VP1 (VP1u) 
genes were amplified by PCR from a plasmid containing a near full-length HBoV 
clone (GenBank accession no. DQ000496). By utilizing restriction sites 
incorporated in the PCR primers (Table 9), the amplicons were cloned into the 
fusion expression vector pET23b (Novagen; Figure 17). The vector incorporates 
an N-terminal T7 tag and a C-terminal hexa-histidine tag (6xHis-tag) into the 
recombinant protein to facilitate detection and purification.  
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Table 9. Primer sequences used to amplify the capsid genes for cloning. 
Amplicon Primers 
VP1u 5’-ATGGAATTCGATGCCTCCAATTAAG -3’ 
5’-GTCCTCGAGTTTTGAGGTTCCTGGTTTAG-3’ 
VP2 5’-GAACGAGCTCCATGTCTGACACTGAC-3’ 
5- GAGGCTTATACTCGAGCAACACTT- TATTG -3 
Note: VP1u, unique part of virus protein 1; VP2, virus protein 2. The restriction sites GAATTC, CTCGAG 
and GAGCTC (marked with bold) are recognized by EcoRI, Xho I and SacI, respectively. 
 
 
Figure 17. The cloning/expression region of the pET-23b vector. Rbs, ribosome binding 
site. 
Expression host. The expression vector construct was chemically transformed 
into the Escherichia coli (E.coli) expression host BL21(DE3)pLysS (Invitrogen). 
The (DE3) designation indicates that the strain carries a chromosomal copy of 
the T7 RNA polymerase gene, which is inducible by IPTG. The pLysS 
designation in turn indicates that the plasmid produces T7 lysozyme, a natural 
inhibitor of T7 RNA polymerase. The presence of T7 RNA polymerase and its 
inhibitor together provide tight control of recombinant protein expression, thus 
inhibiting elimination of the insert from the cell population by natural selection. 
 
Protein preparation. For protein expression, 0.5 l of Terrific broth or Luria 
broth were inoculated with recombinant E.coli and grown at 37°C until the 
culture reached an OD600 of 0.5. The cells were then induced for 3 h with 0.4 
mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and harvested by 
centrifugation. The pellet was resuspended in 25 ml of phosphate buffered 
saline (PBS) and lysed by sonication on ice. The His6/T7-tagged proteins were 
purified under denaturing conditions by nickel-nitrilotriacetic acid (Ni-NTA; 
Qiagen, CA, USA) affinity chromatography in accordance with the instructions 
of the resin manufacturer. 
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7.3.2 EUKARYOTIC HBoV1-4 VP2 EXPRESSION (III) 
Gene synthesis. Genes coding for the HBoV2-4 VP2 were synthesized in the 
pUC57 cloning vector by GenScript Inc. (NJ, USA) based on the GenBank amino 
acid sequences ABW79868, ACR15792 and YP_002916063, respectively. To 
maximize expression of the VP2 genes in Spodoptera frugiperda (SF9 strain) or 
Trichoplusia ni (High Five strain) insect cells, the genes underwent sequence 
optimization by GenScript’s proprietary software to improve codon usage and 
reduce disadvantageous mRNA secondary structures. All sequence 
modifications were such that the amino acid sequences of the original genes 
were not affected. The initiation codons were also placed in an optimal 
translation initiator context [141] and a non-translated sequence shown to 
promote recombinant protein expression was inserted immediately upstream of 
the translation initiation codon [142]. The insert design is illustrated in Figure 
18 with the HBoV3 construct. The nucleotide sequences of the sequence-
optimized HBoV2-4 VP2 gene sequences have been deposited to GenBank with 
the respective accession numbers KF420120, KF420121 and KF425523. The 
cloning of the HBoV1 VP2 baculovirus vector construct has been described 
previously [113]. 
 The bovine parvovirus VP2 gene was amplified by PCR from 
bovine serum with the sense primer 5’-
TCAAAGATCTATGGAGGTATCAAATGATATACC-3’ and antisense primer 5’-
TTGCAGATCTTCACAGGACTTTGTGGTGATTGA-3’. The primers contain the 
Bgl II restriction site for cloning (marked with bold). No additional elements 
were added to the bovine parvovirus VP2 sequence to increase its translation in 
insect cells. 
 
Figure 18. Illustration of the cloning strategy of HBoV VP2 genes with the HBoV3 
sequence as an example. The codon-optimized VP2 gene was preceded by a bacterial 
leader sequence shown to promote expression of recombinant proteins in insect cells 
[142] and the translation initiation codon environment was optimized for efficient 
recombinant protein expression [141]. Two slash characters symbolize the unshown 
portion of the gene. A double stop codon was added to prevent translational read 
through. 
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Cloning. The optimized genes were cloned into the baculovirus transfer vector 
pAcSG2 (Becton Dickinson Biosciences, Franklin Lakes, NJ, USA) under the 
control of the strong polyhedron promoter by standard cloning practices. To 
produce a recombinant baculovirus, SF9 insect cells were co-transfected with 
the transfer vector DNA and linearized baculovirus DNA (BaculoGold, 
Pharmingen, San Diego, CA, USA) using the Fugene6 transfection reagent 
(Roche Diagnostics, Indianapolis, IN, USA) as recommended by the 
manufacturer. The generation of recombinant baculoviruses is illustrated in 
Figure 19. 
 
 
Figure 19. Generation of recombinant baculoviruses. MCS, multiple cloning site. 
Copyright to the insect cell image has been licensed from 123RF Ltd (Hong Kong, 
China). 
Protein expression, purification and biotinylation. For production of 
recombinant proteins, the insect cells were infected with recombinant 
baculoviruses and incubated for 3 days at 27°C. The cells were pelleted by 
centrifugation at 2500×g for 10 minutes at +4°C and resuspended in PBS with a 
protease inhibitor mixture (Complete Mini; Roche Diagnostics, Basel, 
Switzerland) and lysed by sonication. VLPs were purified from the lysate 
supernatant by ultracentrifugation in a 28% cesium chloride (CsCl) gradient (at 
100,000 x g for 24 h, +4°C). 
7.4 IMMUNOASSAYS 
7.4.1 WESTERN BLOT 
Recombinant HBoV1 VP2 and VP1u protein samples purified by Ni-NTA affinity 
chromatography were separated by SDS-PAGE and transferred onto 
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nitrocellulose membranes (Protran BA 85; Whatman, Schleicher & Schuell). The 
membranes were blocked for 30 min with blocking buffer (5% dry milk and 
0.2% Triton-X-100 in PBS) at room temperature. The blocked membranes were 
incubated for 1 h at room temperature with human serum samples diluted in the 
blocking buffer (IgG, dilution 1:50; IgM, dilution 1:30). After each step, the 
sheet was washed 3 times for 10 min each with PBS containing 0.05% 
polysorbate 20 (PBSP). Antibody-conjugate complex was visualized by 
horseradish peroxidase conjugated antihuman IgG or IgM (Dako, Glostrup, 
Denmark; 1:500 dilution) with 3,3’-diaminobenzidine as the substrate and H2O2 
as the oxidizing agent. Stained bands were scored negative or positive before 
knowledge of PCR results. Equivocal results were considered negative. 
7.4.2 ENZYME IMMUNOASSAYS 
 
IgG EIA without antibody absorption. The IgG assays were done in 
indirect format as illustrated in Figure 22. The biotin-streptavidinvi system was 
used to avoid direct contact between the antigen and the polystyrene surface. 
This has the potential to significantly alter the three-dimensional structure of 
conformational antigens [143]. Covalent binding of biotin to the antigens was 
done using the EZ-Link Sulfo-NHS-LC-biotinylation kit (Pierce, Rockford, USA) 
as recommended by the manufacturer. The streptavidin coated plates were 
provided by Thermo-Scientific (Rockford, IL). 
                                                
vi Biotin is a synonym for the water-soluble B7-vitamin whereas streptavidin is a 53 kDa protein of 
bacterial origin. The biotin-streptavidin complex is one of the strongest known protein-ligand 
interactions with a dissociation constant Kd on the order of 10-15 M, i.e. the concentration of free biotin 
required to keep half of streptavidin molecules associated with biotin is no more than 10-15 M. 
Materials and methods 
 68 
 
Figure 20. Schematic presentation of the IgG EIA format used in the thesis. Copyrights 
to the biotin, antigen and IgG images licensed from 123RF Ltd (Hong Kong, China). 
 To attach the biotinylated antigens to the streptavidin plates, the 
antigens were diluted in PBS + 0.05% polysorbate 20 (PBSP) and incubated on 
the plates for 60 min incubation at room temperature in a rocking (400 rpm) 
incubator. In Study III and Study IV 60 ng and 175 ng of antigen per well, 
respectively, was used. This significant increase in antigen load (to increase 
assay sensitivity) was probably made possible by the inclusion of low 
concentration of bovine serum albumin (BSA) in the antigen incubation buffer 
at 25 µg/ml.  
 The wells were blocked against unspecific antibody binding with 
proprietary blocking buffer ("sample diluent buffer"; Labsystems Diagnostics, 
Helsinki, Finland) containing proteins and detergents. Serum samples diluted 
1:200 in PBSP were applied in 100 µl volume and incubated for 60 min at room 
temperature. The plates were washed three times (5 min each time) with PBSP 
and then incubated for one hour with horseradish peroxidase-conjugated rabbit 
anti-human IgG (DAKO, Glostrup, Denmark) diluted 1:2000 in the sample 
diluent. After four washes with PBSP, a mixture of orthophenylene diamine 
substrate and H2O2 was added. The reactions were terminated by adding 100 µl 
of 0.5 M H2O4 and absorbances were recorded at 492 nm after 10 min (Study 
III) or 15 min (Study IV). 
 
IgM EIA without antibody absorption. IgM assays were done in µ-capture 
format as illustrated in Figure 21. Microtiter wells were first coated overnight at 
room temperature with 100 µl of goat anti-human IgM (Cappel/ICN 
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Biomedicals, CA, USA), diluted 1:500 in 0.05 M carbonate buffer (pH 9.6).  
Serum samples diluted 1:200 in PBSP and 0.05% PBSP were applied at 100 
µl/well and incubated 60 min at room temperature. HBoV VLPs were applied at 
25 ng/well and incubated 45 min at 37°C. The plates were then incubated 45 
min at 37°C with 100 µl of horseradish peroxidase–conjugated streptavidin 
(Dako, Glostrup, Denmark) diluted 1:12000 in PBSP with 0.5% BSA. After each 
step, the sheet was washed 5 times with PBSP.  Bound antigen was visualized by 
o-phenylenediamine dihydrochloride (Dako) substrate and H2O2 for 15 min at 
37°C. The reactions were terminated by adding 100 µl of 0.5 M H2O4 and after 
10 min absorbances were recorded at 492 nm. 
 
Figure 21. Schematic presentation of µ-capture IgM EIA. Copyrights to the biotin, 
antigen and IgG molecules licensed from 123RF Ltd (Hong Kong, China). 
Introduction to antibody absorption. Measurement of species-specific 
anti-HBoV antibodies was accomplished with antibody absorption assays. As 
the name implies, these assays utilize a soluble antigen to bind and "inactivate" 
cross-reactive antibodies so that only specific antibodies can bind to the 
immobilized antigen. The assay principle is illustrated in Figure 22, with HBoV1 
VLPs as the absorbing antigen and HBoV2 VLPs as the immobilized detection 
antigen. 
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Figure 22. Antibody-binding phase of HBoV2 EIA assays with and without HBoV1 
absorption. VLP, virus-like particle; H1, HBoV1; H2, HBoV2; Ab, antibody. Copyrights to 
the biotin and IgG molecules have been licensed from 123RF Ltd (Hong Kong, China). 
Antibody absorption in study III. The concentration of soluble VLPs 
required for exhaustive absorption of cross-reactive antibodies was tested in 
Study III by absorbing human sera with varying concentrations of homologous 
VLPs, and was found to be 30 µg/ml. Thus, for the detection of HBoV1-specific 
antibodies, we diluted the sera in PBSP containing soluble unbiotinylated 
HBoV2–4 VLPs (30 µg/mL each). After 1.5 h incubation at +4°C, the sera were 
applied on EIA wells coated with 60 ng of HBoV1 VLPs. 
 A converse approach was applied for the detection of HBoV2-4 
whereby the sera were only absorbed with HBoV1 VLPs. Initial attempts to 
measure fully species-specific results by simultaneous absorptions with multiple 
VLP types reduced most absorbances below the detection level of our assay and 
were discontinued.  
 In all assays, the efficient absorption of the serum samples was 
assessed by testing the samples in parallel with competing VLPs that were 
homologous to the immobilized antigen. These residual optical densities (ODs) 
were typically very low (median 0.05; 90th percentile 0.12). Net ODs were 
calculated by subtracting the residual OD from the raw OD. 
 Other aspects of the EIA assays with antibody absorption (antigen 
amounts, incubation times etc) in Studies III and IV were as detailed above for 
the non-absorption assays. 
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Antibody absorption in study IV. HBoV1 absorption assays followed the 
absorption protocol used in study III. Preliminary HBoV2-4 IgG testing of all 
the children's follow-up samples also followed study III absorption protocol. 
 However, the increased sensitivity of EIA assays in Study IV (see 
above) enabled us to separate between HBoV2 and -3 –specific IgGs better than 
in the Study III. To distinguish between antibodies against these two viruses, 
seroconversion samples with HBoV2 and -3 IgGs in the initial quasi-specific 
screening (as well as the last follow-up sample of these children) were retested 
with species-specific assays. Specifically, the samples with HBoV2 and -3 IgGs 
in the initial screening were reanalyzed for HBoV2 IgG with simultaneous 
HBoV1 and -3 absorption. A similar double-absorption approach was used for 
the analysis of HBoV3 specific antibodies. 
 Testing of HBoV4 specific IgG in Study IV by HBoV1-3 absorption 
was limited to the middlemost and last follow-up sample of each DIPP child. 
This was based on the prior PCR data (chapter 5.2.5) and the results of Study 
III, both indicating that HBoV4 circulation among Finnish children is very rare.  
 For further details on the absorption protocols, please see 
Supplementary Figure 3. 
 
Cutoff determination. In the absence of negative controls to HBoV2-4, the 
EIA cutoff in Study III were determined by a previously described inflection 
point analysis method [144], whereby absorbances from EIA measurements 
were plotted against the rank of each result. The analyses were based on the 
assumption that the ranked random values from uninfected individuals would 
roughly follow a straight line and an exponential deviation from this line at the 
inflection point would be a probable sign of exposure to the immunizing agent. 
The concept of inflection point, as defined in this thesis, is illustrated in Figure 
23. 
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Figure 23. Visual representation of the inflection point as defined in this thesis; i.e. the 
starting point of exponential growth in an XY diagram. 
However, it was later realized that linear correlation between ranks and 
absorbances was based on the false assumption of uniform absorbance 
distribution among the seronegative individuals. In reality, the data are likely to 
follow a normal or lognormal distribution. The interested reader can inspect the 
types of rank vs. absorbance curves that are obtained from a single population of 
lognormally distributed random data in Supplementary Figure 2. Furthermore 
the authors of the inflection point method [144] did not respond to an 
elucidation request, suggesting that the scientific validity of the method could be 
questionable. Fortunately, Study III deals largely with the cross-reactivity of 
HBoV1-4 antibodies, and the interpretation of the said data does not rely heavily 
on precise cutoff values.  
The HBoV1-4 EIA cutoffs were re-established in Study IV by using 
serum samples from the cohort of children with genetic predisposition to type 1 
diabetes (DIPP children; chapter 7.1.4). For IgG-EIA cutoff determination we 
selected samples (n=111) from children aged ≥1 years and before HBoV1 IgM 
seroconversion or HBoV1 viremia. We considered these samples to represent 
non-infected individuals without maternal IgG. Cutoff absorbances [mean + 4 
standard deviations], for positive non-competed and competed IgG EIA results 
from these samples were 0.151 and 0.095, respectively. The same cutoffs were 
applied to the HBoV2-4 EIAs due to an inadequate number of control sera with 
HBoV2-4 IgM seroconversion or HBoV2-4 viremia. 
For determination of the HBoV1 IgM-EIA cutoff, we selected serum 
samples (n = 138) from the DIPP-children aged >8 years on the basis that 
HBoV1 primary infections would be highly uncommon in this age group. 
Samples showing major fluctuations (≥ 0.5 absorbance units) in HBoV1-3 IgG 
absorbances at the sampling point or in neighboring follow-up samples were 
excluded. Cutoffs were calculated as the mean + 4 standard deviations of these 
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absorbances, yielding cutoffs of 0.131 and 0.092 for the respective non-
competed and competed IgM assays. 
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8 RESULTS AND DISCUSSION 
8.1 REAL-TIME QUANTITATIVE PCR DETECTION OF 
HBoV1-4 DNA (I) 
Introduction. In Study I, real-time singleplex assays and a multiplex assay for 
the detection of HBoV1-4 DNA were developed, and their performance as 
diagnostic tools were also evaluated. The multiplex assay is still the only 
published method for the simultaneous detection of HBoV1-4 DNA and no other 
methods for the quantitation of HBoV3 or HBoV4 DNA have been published. 
Using this method, samples are first tested with initial multiplex assay, which 
gives a good estimate of the level of human bocavirus DNA. This preliminary 
screening is followed by singleplex qPCRs of the positive samples to identify and 
accurately quantify the amount of viral DNA. 
 
Sensitivity. The sensitivity of a PCR assay is typically defined as the lowest 
quantity of template per reaction at which 95% of the positive samples are 
detected. These 95% detection limits were determined with serially diluted 
control plasmids. Specifically, testing was done by testing 8 replicates of 10-2 to 
102 plasmid copies per reaction, diluted with pooled (n = 140) fecal DNA 
extracts (chapter 7.1.1) that were qPCR negative for HBoV DNA. The testing was 
repeated with another instrument on a different day. A generalized linear model 
was fitted to the data to determine the plasmid copy number that would yield a 
95% probability of a positive result (Figure 24). Assay sensitivities in fecal DNA 
extracts ranged from ~4 copies per reaction (HBoV2/4) to ~9 copies per 
reaction (HBoV1) for both the multiplex and singleplex assays. The effect of 
human genomic DNA at concentration/amount of 500 ng/reaction on assay 
sensitivity was further assayed. At 10 copies/reaction, 100% of 20 replicates 
were positive with both the multiplex assay (regardless of HBoV species) and all 
singleplex assays. All in all, the assays have a robust limit of detection of ≤ 10 
copies/reaction. 
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Figure 24. Analytical sensitivities of the real-time qPCR assays. The (log) number of 
plasmid copies is indicated on the X-axis and the proportion of PCR positive samples on 
the y-axis. The 95% detection probability level and the corresponding number of 
plasmid copies are indicated with arrows. 
Specificity. The specificities of the qPCR assays were evaluated with cloned 
full-length or near-full-length genomes of Torque teno virus (TTV), parvovirus 
B19 genotypes 1-3, BKV, JCV and simian virus 40 at 1010 copies/reaction. 
Human genomic DNA purified from HeLa cells at 500 ng/reaction was also 
tested. Neither the multiplex nor the singleplex qPCR assays showed observable 
amplification with these specimens. 
 Cross-reactivity of the singleplex assays with HBoV1-4 templates 
was studied with 106 to 109 plasmid copies/reaction. No cross-amplification was 
observed with any of the assays at ≤ 107 copies/reaction and the HBoV1 
singleplex remained specific even at 109 copies/reaction. However, the HBoV2 
and HBoV3 singleplex assays generated borderline positive signals at 109 and 
108 copies of the converse templates, respectively.   
 
Reproducibility. Reproducibilities of the multiplex and singleplex assays were 
studied by replicate analysis of quantification standards in a single run (intra-
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assay variation) and repeated runs (interassay variation). The results are shown 
as coefficients of variation (COVs; ratio of standard deviation to the mean) in 
Study I in accordance with the commonly accepted guidelines for publication of 
quantitative real-time PCR experiments [145]. 
However, COVs by themselves are difficult to interpret. Comparison to 
other papers is also difficult because many papers incorrectly calculate interrun 
variation from quantification cycle data, which is subject to inherent interrun 
variationvii. To facilitate interpretation of assay variances, they are shown in 
Table 10 as averages of absolute deviations, defined as 
 1𝑛 𝑥! − 𝑥!!!!  
 
where 𝑥! is the measured quantity of DNA and 𝑥 is the mean of the three 
replicates.  
 The results show that the assays yield highly reproducible results. 
Even with only 10 nominal copies of template per reaction, the largest average 
deviation across all singleplex assays was only 6.5 copies/reaction. 
                                                
vii Quantification cycle refers to the cycle number at which fluorescence has increased above the 
threshold. Random variation e.g. in the mastermix or the temperature of the halogen lamp used to 
excite the fluorescent molecules can cause a unidirectional shift in the quantification cycles of samples 
and controls. Since the former are determined from the latter, such unidirectional variation in cycle 
numbers is rather meaningless for the accuracy of DNA quantitation.  
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Table 10. Reproducibility of HBoV1, HBoV2/4 and HBoV3 singleplex assays as the 
average absolute deviation. 
  Intra-assay variationa   Inter-assay variationb 
Copies per 
reaction 
 HBoV1 HBoV2/4 HBoV3  HBoV1 HBoV2/4 HBoV3 
101  0.12×101 0.61×101 0.31×101  0.28×101 0.65×101 0.03×101 
102  0.11×102 0.05×102 0.22×102  0.17×102 0.26×102 0.02×102 
103  0.04×103 0.02×103 0.03×103  0.08×103 0.11×103 0.02×103 
104  0.02×104 0.03×104 0.06×104  0.01×104 0.09×104 0.04×104 
105  0.02×105 0.01×105 0.02×105  0.08×105 0.01×105 0.05×105 
106  0.04×106 0.01×106 0.02×106  0.02×106 0.20×106 0.09×106 
107  0.03×107 0.02×107 0.02×107  0.10×107 0.04×107 0.05×107 
108  0.03×108 0.05×108 0.04×108  0.04×108 0.21×108 0.05×108 
Note: average absolute deviation was calculated as !! 𝑥! − 𝑥!!!!  where 𝑥 is the mean of the data set.  
HBoV1-4 incidence in stool. For clinical evaluation of the new qPCR 
methods presented here, stool samples from 250 Finnish travelers and 
nontravelers (chapter 7.1.1) were screened for HBoV1-4 DNA. Five (2%) samples 
were found reproducibly positive for HBoV DNA in the initial multiplex test. Of 
these 5 samples, 4 and 1 were respectively positive with HBoV2 and HBoV3 
singleplex assays, and positivity was further confirmed by sequencing. All four 
HBoV2 positive samples were from children aged <2 years, and the sample with 
HBoV3 DNA was from an 18-year-old individual. Although the absolute number 
of HBoV2-positive subjects was low, the relative HBoV2 prevalence was 12.5% 
among the 32 children aged below 10 years, and 20% among the 20 infants <2 
years of age. Our results are therefore in line with previously reported 
incidences of HBoV2 DNA in stool (Table 4), supporting the specificity of the 
multiplex and (by extension) singleplex assays. Our results also reinforce the 
general consensus that HBoV2 DNA is detected mainly in the stools of children 
aged 5 years or less and rarely among adults. The limited age range of HBoV2 
infections should be taken into consideration when interpreting the percentages 
of HBoV2-positive subjects.  
 
Summary. Specific and highly sensitive real-time singleplex and multiplex 
assays were developed for the detection and quantification of HBoV1-4 DNA. All 
four assays reproducibly detected the genomic sequences of HBoV1-4 down to 
<10 copies/reaction. A single FAM labelled probe is utilized in all four 
singleplex assays and the multiplex assay. This minimizes technological 
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requirements for running the assays and enables the use of virtually all qPCR 
devices. The highly conserved probe sequence may furthermore provide a 
flexible and low-cost platform for the development of qPCR assays for 
additional, yet undiscovered bocaviruses. The results support the view that 
HBoV2 infections are relatively common in young children and rare among 
adults. 
8.2 FIRST STEPS TOWARDS SEROLOGICAL 
DIAGNOSIS OF HBoV1 INFECTIONS (II) 
Introduction.  Diagnosis of acute HBoV1 infections relied initially on PCR 
analysis of respiratory samples. However, it quickly became clear that the line 
between acute and past infections is blurred by the extended presence of the 
virus in the respiratory tract of a significant proportion of infected individuals, 
even up to several months after initial infection [57,65,72,73]. Quantitative PCR 
and serum PCR alleviated the problem but did not entirely resolve it. This is 
because even high levels of HBoV1 DNA can persist for several months or recur 
in the respiratory tract of some children (chapter 5.2.4) and the potential brevity 
of viremia may limit its diagnostic value. PCR-based methods are furthermore 
poorly suited for assessing population-wide exposure to HBoV1-4. 
 To examine whether HBoV infections elicit systemic antibody 
responses and whether these responses could be used for the diagnosis of HBoV 
infections, we initially developed a western blot assay for the detection of anti-
HBoV1 immune responses.  
 
Serological diagnosis of HBoV1 infections. Paired serum samples from 
117 children with acute wheezing were tested by immunoblotting using two 
recombinant HBoV capsid antigens: VP2 and the unique part of VP1 (VP1u). 
The sera were also quantitatively tested for HBoV1 DNA by others [56]. In this 
context, the concept of serodiagnosis is defined as presence of IgM and/or an 
IgG increase (including seroconversion). The subjective interpretation of 
immunoblot results was done before knowledge of the HBoV1 PCR results.  The 
key findings in Study II were: 
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1) VP2 is superior to VP1u with respect to immunoreactivity. According to the 
VP2 assay, 51% and 28% of the 117 children had IgG or IgM, respectively. 
Corresponding VP1u-figures were only 7% and 2%. The following 
immunological results refer to reactivity against the VP2 antigen. 
 
2) HBoV1 NPA load correlates well with serodiagnosis. Of 28 children with 
HBoV1 DNA load <104 copies/ml, 22 (79%) had serodiagnoses. In contrast, of 
the 21 of children with HBoV1 NPA DNA load >104 copies/ml, only 5 (24%) had 
serodiagnoses. 
 
3) All 9 children with the strictest possible non-serological indicators of an acute 
HBoV1 infection (high NPA load, viremia and absence of other respiratory 
viruses) exhibited serodiagnosis.  
 
4) Only 4 of 63 (6%) children without HBoV1 DNA in serum or NPA had a 
serodiagnosis.  
 
The significance of these data for the diagnosis of acute HBoV1 infections by 
NPA PCR will be discussed in chapter 8.6. What is relevant here is how these 
data demonstrate that HBoV1 respiratory infections elicit B cell responses and 
that serological testing is an accurate tool for disclosing acute HBoV1 infections.   
 VP2's superior immunoreactivity in comparison to VP1u was 
surprising considering that VP1u of parvovirus B19 is very immunoreactive and 
has been successfully used in the diagnosis of B19 infections [146]. One 
potential explanation for this dissimilarity could be a difference in the location 
of VP1u within the capsid, influencing its accessibility to the host immune 
system [147]. 
 In contrast to the dissimilar VP1u immunoreactivities, data in the 
Study II indicated that HBoV1 immunity resembles that of B19 with respect to 
the time-related conformational dependence of VP2 antigen recognition. B19 
IgG responses during acute and early convalescence phases are directed towards 
both linear and conformational epitopes of VP2. However, antibodies against 
the linear epitopes disappear within 6 months and only the conformational 
antibodies persist [43]. Our immunoblotting results suggested that this same 
phenomenon affects HBoV1 immunity, since the HBoV1 VP2 IgG 
seroprevalence increased first with age, reaching a maximum of 52% among 
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children aged 1-2 years followed by decrease to 27% among children aged 3-5 
years. The conformational dependence of antibody recognition was later 
supported by results obtained with conformational HBoV1 antigens (Study III), 
showing that HBoV1 IgG seroprevalence among children aged 1-2 years was 
indeed ~50% but, instead of decreasing, continued to increase relatively steadily 
to reach 77% in children aged 5-15 years. This difference in IgG seroprevalences 
between immunoblotting and conformational EIA is unlikely to be due to IgG 
waning and the better sensitivity of the latter method. As discussed in chapter 
8.5, HBoV1 IgG levels are generally stable and appear to remain at a relatively 
high level after primary infection. 
8.3 HBOV SEROLOGY REFINED (III) 
Introduction. The western blot method used in the Study I provided the 
important first steps toward the establishment of serological diagnosis of HBoV 
infection. However, the laboriousness of the assay and its apparent inability to 
detect antibodies of past immunity prompted the development of more 
sophisticated EIA assays [113,137,148]. The combination of these IgG, IgM and 
IgG avidity methods, together with serum PCR, appeared to make HBoV1 
diagnostics a straightforward endeavor. However, the discovery of HBoV2-4 in 
quick succession in 2008 [26] and 2009 [27] raised the concern that these 
closely related viruses could influence the diagnosis of HBoV1 infections. To 
characterize the extent of the serological cross-reactivity and to develop species-
specific antibody assays for all four human bocavirus species, recombinant 
HBoV1-4 viral capsid proteins were produced in insect cells as virus-like 
particles (VLPs) 
 
VLP expression. To produce recombinant antigens for EIAs, insect cells were 
infected with recombinant baculoviruses encoding the VP2 genes of HBoV1-4 
viruses (Study III). With all four constructs, SDS-PAGE verified the high-level 
expression of ~60 kDa VP2. To analyze whether recombinant HBoV VP2s 
possess the capacity to spontaneously assemble to VLPs in insect cells, the 
proteins were purified by CsCl and examined by electron microscopy. Distinct 
parvovirus-like capsid structures with an approximate diameter of 21–25 nm 
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were observed with all four constructs as exemplified by HBoV2 VP2 VLPs in 
Figure 25. 
 
 
Figure 25. HBoV VP2 expression and purification with HBoV2 as a representative 
example. A) SDS-PAGE of non-infected (lane 1) and baculovirus-infected (lane 2) 
insect cells. B) SDS-PAGE of purified HBoV2 VP2. C) Electron micrograph of purified 
HBoV2 VLPs. Scale bar = 100 nm. 
Antibody cross-reactivity. The VLPs were used in Study III to evaluate the 
cross-reactivity of anti-HBoV antibodies. The evaluation was done with human 
sera and with rabbit antisera produced against the HBoV1 or HBoV2 VLPs.  The 
rabbit antisera were diluted serially and then tested by EIA (without absorption) 
for their reactivity to HBoV1-4 to determine the antibody endpoint titers.  We 
also tested the antisera in a similar fashion against the VLPs of two other human 
parvoviruses and an animal bocavirus, namely human parvovirus B19, PARV4 
and bovine parvovirus. Phylogenetically unrelated Merkel cell polyomavirus 
(MCPyV) VLPs were purified with the same method as the parvovirus VLPs and 
used as controls for unspecific binding. 
 Both HBoV1 and HBoV2 antisera showed clear cross-reactivity 
towards the other three bocaviruses in relative to the MCPyV negative control 
(Figure 26). Interspecies HBoV antibody titers were approximately 102-103 
lower than homologous titers. Bovine parvovirus VLPs were unreactive with 
both antisera but surprisingly B19 and PARV4 VLPs showed modest reactivity. 
However, the almost linear shape of the B19 and PARV4 curves, as opposed to 
the inverse sigmoidal seen with HBoV antigens, may indicate random antibody 
binding rather than recognition of conserved epitopes. 
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Figure 26. Endpoint dilutions of HBoV1 and HBoV2 rabbit antisera as indicated by the 
titles. The curve legends indicate the type of virus-like particle (VLP) that was used for 
antibody detection. The sera were studied with serial dilutions as indicated on the x-
axis. Merkel cell polyomavirus (MCPyV) VLPs were used as a negative control to 
account for unspecific binding. The preimmune serum of the HBoV2 rabbit was the only 
preimmune sample to show antibody reactivity towards the VLPs before immunization 
and is also shown. 
To assess the cross-reactivity of anti-HBoV antibodies in human sera among 
subjects with long-term immunityviii, we measured the IgG reactivity of 115 
serum samples from Finnish medical students with and without antibody 
absorption (Study III). The prominent effect of HBoV1 VLP absorption on the 
HBoV2-4 VLP reactivity of the sera is illustrated in Figure 27. The respective 
frequencies of HBoV2-4 IgG detection among the 115 adults were 96%, 87%, 
and 78% without absorption. HBoV1 absorption reduced these figures to 29%, 
8% and 1%. HBoV1 seroprevalence and absorbance levels were affected more 
modestly by HBoV2-4 absorption, reducing the seroprevalence from 95% to 
64%. In addition to significant cross-reactivity in human sera, the data illustrate 
that HBoV1 infections are significantly more frequent and/or elicit stronger 
antibody responses than HBoV2-4 infections. A more detailed discussion of 
HBoV1-4 seroprevalences will be found in chapter 8.5. 
                                                
viii  That the vast majority of these sera do in fact represent past-immunity phase of infection will be 
substantiated in chapter 8.5, showing that most individuals are infected by HBoV1 by the age of 5 years. 
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Figure 27. Immunoglobulin G (IgG) reactivity of 115 sera from Finnish medical students 
with HBoV1-4 virus-like particles (VLPs). Results are shown with and without antibody 
absorption as indicated by the top legends. 
We also investigated the cross-reactivity of anti-HBoV IgG in individual medical 
students by monocompeting the serum samples with increasing concentrations 
of recombinant antigen (III). The sera were selected from individuals with IgG 
for only one bocavirus species. The results are illustrated in Figure 28. Neither 
human parvovirus B19 nor MCPyV absorption resulted in any observable 
reduction in absorbances, whereas absorption with heterologous HBoV antigens 
resulted in significant decrease in absorbance levels regardless of the underlying 
anti-HBoV IgG type of the seropositive individuals (Figure 28).  
 
Figure 28. Monoabsorption of HBoV1, -2 or -3 IgG positive serum samples with various 
concentrations of homologous (colored curves) or heterologous (black curves) VLPs as 
indicated by the curve legends. The sera were selected from adults based on the 
presence of IgG for only one HBoV species as indicated by the image titles. The titles 
also indicate the type of VLP used for IgG detection. Merkel cell polyomavirus (MCPyV) 
VLPs were used to control for nonspecific competition. 
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To assess the cross-reactivity of acute-phase HBoV1 antibodies, we used paired 
sera from 21 wheezing children with a thoroughly characterized acute HBoV1 
infection (II); all seroconverted for IgG, were viremic, and tested positive for 
IgM, and 17 (80%) also had HBoV1 DNA in NPA. Based on the results above, we 
expected these sera to show significant cross-reactivity in HBoV2-4 EIAs. 
However, to our surprise, we initially discovered that all these acute-phase sera 
were non-reactive in HBoV2-4 IgM EIAs and most were also unreactive in 
HBoV2-4 IgG EIAs (Figure 4A in Study III). Based on these initial results, it was 
suggested in Study III that antibodies against HBoV1 and possibly against 
HBoV2-4 are highly specific at the acute phase of infection but become more 
cross-reactive as the B cells mature and the affinity of the antibodies increases. 
 However, in Study IV the sensitivities of IgG and IgM EIAs were 
enhanced by increasing the amount of detection antigen and substrate 
incubation time as detailed in chapter 7.4.2. The increased sensitivity of the 
assays was counterbalanced by reduced interspecies HBoV specificity. With the 
enhanced IgG assay, sera from the children with acute HBoV1 infection were 
clearly reactive with HBoV2-4 VLPs (Figure 29; unpublished results), 
counteracting the previous claim of high specificity of acute-phase IgG (Study 
III). Similar results were obtained with the enhanced IgM assay. The previous 
proposition of highly specific HBoV antibodies in the acute phase of infection 
(as opposed to past-phase of infection) must therefore be rectified by 
acknowledging that the specificity depends heavily on the experimental 
methodology. 
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Figure 29. HBoV1-4 IgG reactivities of paired sera from 16 wheezing children (without 
antibody absorption) The sera were selected based on IgG seroconversion to HBoV1 
VLPs, and most showed multiple markers of acute HBoV1 infection (IgM, viremia and 
HBoV1 DNA in NPA). This figure should be considered as an updated version of Figure 
4A in Study III to reflect Study IV's improved assay sensitivities. 
 Since the results clearly demonstrate that anti-HBoV antibodies 
are cross-reactive, it is necessary to define concise symbols for results obtained 
without or with antibody absorption. Thus the subscript "a" (for "absorbed") 
will be used in the following chapters to denote the latter results, as in IgGa or 
IgMa. Absence of a subscript refers to results obtained without antibody 
absorption or, depending on the context, is a general reference to IgG or IgM 
antibodies. 
 
Antibody absorption & EIA sensitivity. Antibody absorption assays block a 
significant portion of the total anti-HBoV antibody population and therefore 
reduce the sensitivity of the antibody assays (illustrated in Figure 22).  This is 
demonstrated by Study III, in which it is showed that all 115 Finnish medical 
students were IgG positive for one or more HBoVs when measured without 
antibody absorption. Yet, in the competition assays, 16 (14%) individuals 
appeared negative for HBoV1-4. The situation improved by the development of 
the more sensitive EIA protocols (Study IV). By the new assays, only 2 of the 115 
(1.7%) Finnish medical students were negative for HBoV1-4 IgGa (unpublished 
results).  
 Despite this improvement in assay sensitivities, absorption assays 
consume very large quantities of antigens, which are laborious to produce and 
expensive to purify. Large-scale serological studies or routine inspection of anti-
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HBoV antibodies calls i) for the development of EIAs that are not dependent on 
antibody absorption or ii) more advanced antigen production and purification 
methods. One future possibility is an EIA assay based on monoclonal species-
specific HBoV1-4 antibodies (mAbs), which could then be competed with 
human serum antibodies. A reduction of absorbance in the mAb assay would 
indicate the presence of species-specific antibodies in the human serum. 
Another potential alternative for the identification and differentiation of acute 
HBoV1-4 infections is the screening of species-specific HBoV protein epitopes 
by epitope scanning. Indeed, a linear VP2 epitope suitable for the diagnosis of 
acute parvovirus B19 infection has been identified [149]. In Study II the 
groundwork for this kind of approach was laid by demonstrating that in linear 
form the HBoV1 VP2 antigen is highly reactive with acute-phase serum samples 
and superior in immunoreactivity to the unique region of the HBoV1 VP1 
antigen.  
 
Summary. As shown here and later confirmed by others [150], antibodies 
against HBoV1-3 show significant cross-reactivities, and correction for this is a 
prerequisite for VLP-based HBoV serology. Data regarding HBoV4 is scarce but 
there is no reason to assume that the virus would be antigenically distinct from 
the other HBoVs. Antibodies in acute-phase sera appear to be less cross-reactive 
than matured past-immunity antibodies but even acute-phase sera can cause 
false positive results in sufficiently sensitive HBoV antibody assays. 
 The cross-reactive antibodies can be blocked by antibody 
absorption but this reduces the sensitivity of the EIA assay. Antibody absorption 
also requires relatively high amounts of competing antigen and multiplies the 
number of analyses required for reliable results. For these reasons, new 
approaches should be considered for species-specific serodiagnosis of HBoV 
infections. 
8.4 IMMUNOLOGICAL EFFECTS OF CONSECUTIVE 
HBoV INFECTIONS (IV) 
Introduction. Significant cross-reactivities of anti-HBoV antibodies raised the 
possibility that antibody responses in consecutive heterologous HBoV infections 
could be influenced by the original antigenic sin phenomenon (OAS). As 
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discussed in chapter 5.3.1, OAS can be shortly defined as inhibited activation of 
naïve B or T cells toward a secondary antigen due to pre-existing immunity to a 
previously encountered (related) primary antigen. Such a non-optimal immune 
response could potentially lead to a more severe disease. Alternatively, the 
antigenic similarity of HBoV capsids could manifest as cross-protective 
immunity. We aimed to investigate the existence of these two phenomena by 
comparing the strength and frequency of HBoV primary infections to those of 
heterologous secondary infections.  
 To discuss the matter more concisely, the word “primed” will be 
used in this chapter to refer to children who had IgGa for one bocavirus before 
infection by another bocavirus. For example, the phrase “primed children with 
HBoV1 viremia” refers to children showing (persistent) HBoV2, -3 or -4 IgGa 
before showing HBoV1 viremia.  
 
Codetection of IgG & IgM. Among the DIPP cohort, it was found that HBoV1 
IgGa occurred more rarely in patients with HBoV2 IgGa and vice versa (IV). 
Specifically, all 51 HBoV2 IgGa negative subjects showed HBoV1 IgGa but only 
43 of 58 (74%) HBoV2 IgGa positive subjects showed HBoV1 IgGa (p<0.0001 by 
the Fisher's exact test). When IgGa for two different bocaviruses were present 
simultaneously, reactivity toward the second virus was in general significantly 
lower than what was observed in non-primed individuals. For example, HBoV1 
IgGa absorbance in all 68 non-primed children remained >1.0 after the initial 
seroconversion in contrast to only eight of 22 (36%) of children primed with 
HBoV2 or -3.  
 These results were observed with IgG assays that relied on 
antibody absorption. Since this technique may complicate the interpretation of 
the results, an HBoV1 IgM assay that does not require antibody absorption for 
high specificity (demonstrated in Study III, Figure 4B) was used to confirm the 
findings. It was found that (without antibody absorption) HBoV1 IgM occurred 
in 32 of 55 (58%) children in whom HBoV1 was the first infecting HBoV but 
only in one of 23 (4%) of children who were primed with HBoV2 or -3 before 
HBoV1 IgG seroconversion. The infrequent occurrence of secondary IgM in 
addition to secondary IgG in primed children is in line with the OAS 
phenomenon, since the production of both antibody classes originates from 
naïve B cell activation. Activated cells first secrete IgM but are later converted to 
IgG-secreting plasma cells through immunoglobulin class switching (reviewed 
Results and discussion 
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in [151]). Results from both the IgG and IgM assays therefore support the view 
that priming with HBoV2 or -3 decreases the likelihood of observing a 
subsequent seroconversion for HBoV1. Similarly, priming with HBoV1 decreases 
the likelihood of observing a subsequent seroconversion for HBoV2 or -3. Low 
frequency of secondary (heterologous) seroconversions may also reflect cross-
protective immunity e.g. via cross-neutralizing antibodies.  
 
Viremia. The above results demonstrate that priming can significantly reduce 
antibody responses against novel epitopes of another bocavirus species or 
protect against heterologous infections. However, they do not tell if priming has 
the potential to completely prevent serological (species-specific) identification 
of secondary infections if one has indeed taken place. To gain further insight 
into immunological aspects of secondary bocavirus infections, it is essential to 
inspect a diagnostic marker that does not depend on the activation of naïve B 
cells, is unlikely to be caused by aerial contamination and is a highly probable 
sign of an acute infection: viremia. 
 Among the DIPP cohort, five primed children with HBoV1 viremia 
and four primed children with HBoV2 viremia were identified. Two of the five 
HBoV1 viremias and all four HBoV2 viremias failed to result in a detectable IgGa 
response specific for the viremic species. IgGa responses that did take place 
against the viremic species were generally much weaker than in non-primed 
children. To illustrate these results, the complete IgG profiles (i.e. with and 
without antibody absorption) of two primed children (#122, #114) with HBoV1 
or HBoV2 viremia are shown in Figure 30. Child 122 showed HBoV1 viremia at 
the age of 4 years without developing HBoV1 IgGa, whereas child 114 showed 
HBoV2 viremia slightly before the age of 8 years and developed only a 
borderline HBoV2 IgGa response.  The complete IgG profiles of two 
representative non-primed viremic children (#53, #31) are shown for 
comparison. The interested reader can also find as an online supplementary 
data the IgG profiles of all 109 children of the DIPP cohort using the digital 
object identifierix  (DOI) 10.6070/H4ST7MRT. The IgG profiles of the three 
children who were primed with HBoV2 but managed to generate an antibody 
response against a viremic HBoV1 infection appear in the supplementary file as 
cases #15, #36 and #69. 
                                                
ix The DOI code can be translated into a web address at dx.doi.org. For more information on DOI 
codes, please see the Foreword (chapter 4). 
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Figure 30. Representative IgG profiles of two primed (114, 122) and non-primed (31, 
53) children with HBoV1 or HBoV2 viremia (for the definition of the word "primed" as 
used here, please see the introduction paragraph of the current chapter). There are 
three graphs for each subject and a row corresponds to one subject. The black, blue 
and red data points respectively indicate whether the serum has not been tested by 
PCR, has been negative by PCR or has been tested positive by PCR. Red open circles 
and rectangles respectively indicate that the sample has been IgM positive for HBoV1 
or HBoV2. Heterologous absorption (middle graphs) here means that HBoV1 IgGa 
measurement has been done with HBoV2 and -3 absorption whereas HBoV2 IgGa 
measurement has been done with HBoV1 absorption. The rightmost graphs are from 
homologous absorption (i.e. same antigen used for measurement and absorption) to 
control the thoroughness of the absorption. Note that these children tested negative for 
HBoV3 IgGa. For more information on the absorption procedures, please see chapter 
7.4.2. 
As an alternative to the OAS interpretation, one could perhaps argue that not all 
HBoV viremias result in IgGa responses regardless of the preexistence of 
antibodies towards other bocavirus species. In the case of HBoV1, this seems 
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very unlikely considering that all the documented HBoV1 viremias in non-
primed children were associated with very strong IgGa responses, as exemplified 
by child 53 in Figure 30. The only exception is the child #65 (see the online 
supplement) but this individual had maternal HBoV1 IgGa during the viremic 
period. IgGa responses to viremic HBoV2 or HBoV3 infections in unprimed 
individuals were generally weaker than those against HBoV1, but hardly weak 
enough to support non-immunogenic viremias in unprimed individuals.  
 The results point to a remarkable similarity between the 
serodiagnostic aspects of HBoV and dengue virus (DENV) infections. The 
identity of the priming DENV serotype can be determined by measuring which 
serotype the patient's serum sample neutralizes most efficiently. In line with 
OAS, the highest titer is against the priming serotype even after infection by 
other serotypes [152]. However, despite a few decades of research, there is no 
proven serologic method to reliably determine the serotype responsible for a 
secondary DENV infection. One recent study [153] used a multinomial logistic 
regression model to infer the secondary infecting serotype with 68% accuracy 
based on the patient's pre- and postinfection neutralizing antibody titers (the 
true serotype had been determined by blood PCR). The model inferred the 
infecting serotype correctly in 60% of cases if only the postinfection 
neutralization titer was known (as would be the case in most clinical settings).  
 Analogously to neutralizing antibody titers against dengue viruses, 
a secondary bocavirus infection could potentially in the future be identified by 
comparing pre- and postinfection antibody titers against shared and specific 
HBoV epitopes. A homologous reinfection should efficiently stimulate the 
generation of IgG and IgGa against the priming species whereas one might 
expect a heterologous infection to result only in the generation of antibodies 
against epitopes that are shared with the priming bocavirus species. 
Furthermore, as indicated by the regression model used to type DENV 
infections, relative increases in antibody titers towards the cross-reacting 
epitopes could identify the secondary species involved in the infection.  
 However, as indicated by the ambiguousness of DENV serology, 
precise typing of the secondary infections could be impossible. Even serological 
separation between homologous and heterologous secondary infections by 
comparing changes in IgG and IgGa titers could prove very challenging. This is 
due to the possibility that the second HBoV species may stimulate B-memory 
cells specific for the first HBoV species. Whilst such an effect may seem 
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paradoxical, it has been observed as early as 1974 by Virelizier and colleagues 
who examined immune responses against purified H0 and H1 hemagglutinin, 
representing two influenza strains [121]. The authors suggested two possible 
explanations:   
 
“Either T-memory lymphocytes, with a broader specificity than 
the B lymphocytes, are triggered by the cross-reacting antigen and are then 
able to help B-memory lymphocytes to secrete antibody specific for the first 
antigen, as suggested in other systems, or B-memory cells with specificity for 
the first antigen are directly triggered by the cross-reacting antigen. Our 
results favor the latter hypothesis, since Ho-primed spleen cells transferred 
after treatment with anti-θ serumx and complement were able to secrete anti-
Ho antibody in either irradiated or thymus-deprived recipients after a boost 
with H1. “ 
 
Child #114 in Figure 30 could be example of this type of phenomenon. At the 
age of 8 years, one can see HBoV2 viremia followed by borderline HBoV2 IgGa 
response and a clearly stronger HBoV1 IgGa response. Simultaneously, the child 
shows a very strong rise in IgG against epitopes shared between HBoV1 and 
HBoV2. The absolute number of similar cases in the DIPP cohort cannot be 
determined because the EIA absorbances in many children were already near 
the saturation point (Abs > 3.0) of our assays. Proportional estimates can 
nevertheless be made by examining children with absorbance values under 
saturation level (<3.0) before the secondary heterologous IgGa seroconversion. 
Of 28 such children, 11 (40%) showed a coincident increase in IgGa (ΔAbs ≥1.0) 
against the priming bocavirus species. 
 Due to the implications of OAS, the interpretation of the 
serological data is challenging and the possibility of heterologous IgGa boosts 
complicates it even further. Let us examine e.g. the child #115 (Figure 31). At the 
age of ~6 years, this child showed a sudden very sharp increase in non-absorbed 
IgG towards HBoV2 and HBoV3 and a simultaneous increase in IgGa towards 
HBoV1. If one were to set aside heterologous IgGa boosts, the secondary 
increase in HBoV1 IgGa would be interpreted as an obvious sign of a re-exposure 
to HBoV1. However, the notion of heterologous boosting and a comparison of 
the IgG and IgGa absorbances in the two figures offers an alternative 
                                                
x anti-θ serum contains cytolytic antibodies against T-cells  
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interpretation. Before the antibody boost, the IgG and IgGa curves show a very 
good correlation with the latter showing only slightly lower absorbance values 
than the former. After the antibody boost, HBoV1 IgGa absorbance quickly 
decreases back to the pre-boost level but the non-absorbed IgG absorbance 
remains at very high level with all three antigens. This change is especially 
noteworthy regarding the HBoV2 and -3 IgG absorbances that were near cutoff-
level before the boosting event. Thus, this case could be an example of strong 
heterologous IgGa boost combined with the OAS phenomenon.  Although 
strongly speculative, this demonstrates the complexity of untangling the 
serological data.  
 
 
Figure 31. Speculative example of a heterologous HBoV IgGa boost by an enteric 
bocavirus. See Figure 30 footnote for descriptions of the symbols.  
OAS vs. cross-immunity. The term "original antigenic sin" is wordplay that 
refers to the Christian theological doctrine of Adam and Eve tasting the 
forbidden fruit in Eden, and the consequences of this incidentxi. As already 
discussed in chapter 5.3.3, the phenomenon has at least theoretical potential to 
result in aggravated viral infections. However, the negative undertone of the 
term may not necessarily be justified in the context of human bocaviruses. This 
is because protective aspects of HBoV immunity could explain most 
manifestations of the phenomenon that we have seen in the preceding chapters. 
As already discussed in chapter 5.3.2, preexisting immunity against the priming 
bocavirus species may significantly limit the capability of the secondary species 
to propagate by eliminating infected cells with cytotoxic T cells targeting 
conserved epitopes. Second, some of the cross-reactive antibodies may directly 
                                                
xi Genesis 3:16-19: Then God said to the woman, "I will sharpen the pain of your pregnancy, and in pain you will give 
birth. And you will desire to control your husband, but he will rule over you". To Adam he said, “Because you listened to your 
wife and ate fruit from the forbidden three, cursed is the ground under your feet; through painful toil you will eat food from it 
all the days of your life. It will produce thorns and thistles for you, and you will eat the plants of the field. By the sweat of your 
brow you will eat your food until you return to the ground; for dust you are and to dust you will return.” 
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neutralize the secondary virus or facilitate its elimination through phagocytosis. 
Even in the absence of robust responses against the unique epitopes of the 
secondary bocavirus, together these factors and the innate immunity could 
potentially prevent secondary HBoV infections entirely or reduce the incidence 
of systemic infections by preventing the spread of the virus. 
 The protective or exposing effect of HBoV priming could 
potentially be examined by comparing the occurrence and severity of symptoms 
associated with primary infections and secondary heterologous infections. 
However, the number of children with secondary HBoV seroconversions was 
insufficient for meaningful statistical analysis. Symptoms associated with 
primary HBoV infections will be discussed in chapter 8.7.   
 One could also attempt to compare the magnitudes and 
frequencies of viremias in primary and secondary infections. However, this was 
complicated by the non-constant sampling intervals, which were doubled 
beyond 2 years of age. Since the likelihood of viremia detection is directly 
proportional to the frequency of sampling and children with primary infections 
were on average younger than children with secondary infections, the rates of 
viremias in the two groups cannot be directly compared. Age matching was 
attempted to circumvent this problem but the number of matched children was 
insufficient for a meaningful statistical analysis.  
 
Summary. Pre-existing immunity against HBoV1 is associated with weak or 
non-detectable immune responses against the following HBoV2 infections and 
vice versa. This suggests that close antigenic similarity of HBoV1-4 gives rise to 
the OAS phenomenon, cross-protective immunity or both. However, the 
absence of detectable IgGa responses to viremic infections in some primed 
individuals suggests that the results are not only due to cross-protective 
immunity preventing secondary infections. These observations have important 
implications for the interpretation of serological HBoV data and emphasize how 
the accurate diagnostics of HBoV1 and -2 (and possibly -3 and -4) infections 
calls for the parallel use of nucleic acid and serodiagnostic methods. Future 
serodiagnostic methods to identify secondary HBoV infections could potentially 
be based on the relative strengths of antibody responses against species-specific 
and shared HBoV epitopes. 
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8.5 HBoV1-4 IgG SEROPREVALENCE AND 
LONGEVITY (IV) 
Introduction. Since the discovery of HBoV1 in 2005, several serological 
surveys have assessed its seroprevalence [148,154-158]. These studies have 
uniformly reported that HBoV1 seroconversions occur early in life and that 
HBoV1 IgG is found in almost all adult individuals. However, this thesis project 
is the first to assess HBoV1 seroprevalence with species-specific antibody assays 
that take into account the cross-reactivity between HBoV1-4. This is also the 
first assessment of HBoV2-4 seroprevalences among adults and children.  
 
Seroprevalence. In Study IV in which 109 children were followed almost from 
birth to early teens by sequential serum sampling, all children became 
seropositive for one or more HBoV species by the age of 4.8 years. The median 
ages of HBoV1-3 seroconversions were 1.9, 1.7 and 1.6 years, respectively, with 
no statistically significant difference. The most commonly detected IgGa 
seroconversions were, in descending order, against HBoV1, -2 and -3. HBoV4 
IgGa was not detected in any of the children. Frequency distributions of HBoV1-
3 seroconversions in various age groups are illustrated in Figure 32. The 
cumulative and non-cumulative seroconversion frequency distributions in the 
graph differ from each other because some of the children reverted to 
seronegative status. HBoV1-3 IgGa seroreversions were evident in 10 (11%), 13 
(22%) and 3 (30%) of the seroconverted children, respectively. Approximately 
half of the IgGa seroreversions occurred in children with very low-level IgGa 
responses that lasted only one or two sampling intervals (e.g. child #110 in the 
supplementary data). The other half occurred in children with weak or moderate 
IgGa responses that waned below the cutoff level over the course of a few years 
(e.g. child #14 in the supplementary data). 
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Figure 32. Cumulative (lines) and non-cumulative (blocks) frequency distribution of 
human bocavirus IgGa seroconversions in different age groups. Seroprevalences are 
shown with dashed lines. 
The reader is cautioned that, due to the probable influence of OAS, the 
true incidence of HBoV1-3 infections is likely to be higher than that indicated by 
the seroprevalence figures. It is also possible that the HBoV2-4 EIA assays are 
not sensitive enough, since the protocols are based on the HBoV1 EIA assays 
and not individually optimized for HBoV2-4 IgG detection (discussed in the end 
of chapter 7.4.2). The figures shown herein should therefore be considered 
minimum estimates of the incidence of HBoV1-3 infections in Finland. For 
comparison, a Chinese study [150] examined HBoV seroprevalences in different 
age groups and found that approximately 60%, 50%, 40% and 0% of children 
aged 5-14 years were positive for HBoV1-4 specific antibodies, respectively. The 
most significant differences to the results presented in this thesis are the low 
HBoV1 IgGa seroprevalence and high HBoV3 IgGa seroprevalence. This could 
indicate that there are significant regional differences in the relative incidences 
of HBoV1-3 infections. However, PCR data does not appear to support the wide 
circulation of HBoV3 in China. Studies assessing the incidence of HBoV DNAs 
in Chinese stool specimens [100,106] have been consistent with corresponding 
western studies (chapter 5.2.5), showing that HBoV3 DNA is found very 
infrequently.  
Our studies III and IV and this Chinese study, published 9 months after 
Study III, are currently the only published analyses of HBoV1-4 
seroepidemiology that have taken into account serological cross-reactivities 
between HBoVs. 
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IgG longevity. IgG longevity varied greatly between individual children, but 
generally HBoV1 IgGa profiles were characterized by strong initial 
seroconversions that remained at high level throughout the sampling period 
(e.g. child 53 in Figure 30). HBoV2 IgGa profiles were characterized by sharp 
increases and decreases in absorbance and generally the absorbance levels were 
lower than those of HBoV1 (e.g. child 122 in Figure 30). The number of HBoV3 
positive subjects was too low for firm conclusions to be drawn but the IgGa 
profiles of the few seropositive children resembled those of HBoV2.  
 Weak and/or waning IgG responses to HBoV2 and HBoV3 are 
supported by the low IgGa levels among the Finnish medical students (Study III; 
Figure 27). Of note is also the finding that maternal IgGa against HBoV1 was 
detected in 51% of 88 DIPP children from whom the first serum sample was 
taken within 6 months from birth (Study IV). Maternal IgGa against HBoV2 or 
HBoV3 occurred only in 7% of this same group of children, further indicating 
low antibody levels in adult women. Distinction between maternal HBoV2 and 
HBoV3 IgGa was not possible in absorption assays due to low antibody levels.  
 
Summary. Serological results support PCR-based findings that the HBoV 
species most frequently infecting humans are, in descending order, HBoV1, 
HBoV2, HBoV3 and HBoV4. HBoV1-3 infections occur early in childhood. 
There was significant variability in IgGa stability between individual children 
but typically HBoV1 IgGa levels remained high and stable, whereas HBoV2 IgGa 
levels were markedly lower and characterized by sharp fluctuations. These data, 
together with the infrequent occurrence of HBoV2 viremia among children (next 
chapter), may indicate that the enteric bocaviruses typically cause local 
infections of the intestinal tract rather than systemic infections like HBoV1. 
8.6 HBoV DNA AS AN INFECTION MARKER (II, IV) 
HBoV1 DNA in respiratory samples. The week or so required for the 
primary adaptive immune response to develop against an infecting pathogen is 
the time when the body is especially vulnerable and the clinical symptoms of the 
infection can typically be expected to manifest. To assess the pathogenicity of a 
novel virus, it is important to know how well a diagnostic test can distinguish 
the acute phase of infection from the recovering (convalescent) or past phase of 
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infection. Inability to distinguish between the phases could significantly reduce 
the correlation between infection and disease. 
 To assess the diagnostic significance of finding HBoV1 DNA in 
nasopharyngeal aspirates (NPAs), NPA PCR positivity was compared to the 
occurrence of HBoV1 IgM and IgG in paired serum samples from 117 children 
with acute wheezing (Study II). The first of the two serum samples was obtained 
at hospital admission (acute sample) and the second sample 2-3 weeks later 
(convalescent sample). A serodiagnostic result was defined as the presence of 
IgM in either of the two consecutive samples or a significant increase in IgG 
between the two samples.  
 As discussed in chapter 8.2, 24 of the 28 (96%) wheezing children 
with high HBoV1 viral NPA load showed HBoV1 serodiagnosis (Study II). In 
contrast, only five of 21 (24%) children with low viral NPA load showed HBoV1 
serodiagnosis. Allander and colleagues had previously tested most of these same 
sera for HBoV1 DNA and found 94% of children with high NPA load to have 
HBoV1 DNA in acute serum as opposed to only 11% of children with low load 
[56]. Together these results are consistent with the presence of relatively high 
NPA load at the acute phase of infection and with subsequent low-level 
persistence. Indeed, several later studies have confirmed that HBoV1 DNA may 
persist or reappear in respiratory airways for up to several months after primary 
infection [57,65,72,73]. For example, a Finnish study [72] found that 11% of 152 
immunocompetent children showed prolonged (or intermittent) presence of 
HBoV DNA for at least 3 months whereas a Danish prospective birth cohort 
study [65] found that 25% of immunocompetent children remained positive for 
HBoV DNA for at least 2 months. The poor diagnostic value of qualitative 
HBoV1 NPA PCR may be further exacerbated by the frequent exposure of 
children to HBoV1 DNA by their infected peers, e.g. in day care. The extreme 
sensitivity of modern DNA detection methods makes it possible that inhalation 
of exogenous HBoV1 DNA can yield a positive PCR result without causing 
infection in a seropositive individual. It is also possible that low-level HBoV1 
DNA in the respiratory tract is indicative of a superficial or a very localized 
infection without systemic immunization. If this indeed is the case, such 
superficial infections are unlikely to result in significant symptoms and would 
further reduce the usefulness of non-quantitative DNA assays in HBoV1 
diagnostics. 
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 However, even high HBoV1 NPA load is not a definite marker of 
recent infection. This has been demonstrated in two relatively recent studies.  
Lehtoranta and colleagues [72] showed that ~10% of 152 otitis-prone children 
exhibited prolonged presence of HBoV DNA for ≤3 months. Of these prolonged 
cases, approximately half had respiratory viral loads that remained above 104 
copies/ml. Furthermore, Martin and colleagues [57] observed in 3 out of 70 
HBoV1 DNA-positive (constitutionally healthy) children viral loads of 106 
copies/ml more than a month after initial PCR positivity.  
 
Prologue to HBoV viremias. Because of the discovery of HBoV1 from 
nasopharyngeal aspirates and HBoV2-4 from fecal samples most studies have 
assessed the involvement of HBoV1 in respiratory and HBoV2-4 in 
gastrointestinal disease. However, viremic (or "systemic") infections result in 
the distribution of the viruses throughout the body and this may give rise to 
symptoms of other types. Understanding the tendency of HBoV1-4 to cause 
viremia therefore facilitates the assessment of their possible etiological roles. On 
the other hand, the duration of viremia determines its diagnostic value in the 
identification of acute HBoV infections. 
The incidence and duration of HBoV1-4 viremias were analyzed in 
the wheezing children (studies II & III) and the DIPP children (Study IV). Most 
serum samples from the wheezing children were analyzed for HBoV1 DNA in 
studies that are not part of this thesis [56,113] but testing for HBoV2-4 DNA was 
done as part of Study III. For the PCR study of the DIPP sera, we devised a 
serological selection method to limit the testing to 564 samples of the entire set 
of 1943 samples. Specifically, quantitative PCR was done on the three specimens 
flanking each primary or secondary increase (>1.0 absorbance units) in anti-
HBoV1-3 antibodies as illustrated in Figure 33.  
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Figure 33. Sample selection for studying the incidence of viremia in the DIPP cohort 
was based on IgG fluctuations. The image illustrates (without absorption of cross-
reactive antibodies) the HBoV1-3 IgG absorbances of child #52 followed ~7 years from 
birth. All samples showing an >1 absorbance unit increase in IgG for any of the three 
viruses were included in the screening, as well as samples flanking these increases. 
PCR negativity and positivity are indicated by blue and red colors, respectively. 
Samples that did not meet the inclusion criteria are shown with black symbols. 
HBoV1 viremias. Among the 117 wheezing children, diagnostic HBoV1 
antibody results coincided almost invariably with HBoV1 viremia. Of the 29 
children with an HBoV1 primary infection according to immunoblot analysis, 27 
(93%) were viremic (Study II). An extended cohort of 258 wheezing children 
that included these 117 subjects was later analyzed by HBoV1 VLP EIA. This 
study showed a very similar result; of 48 children with serologically diagnosed 
acute HBoV1 infection, 45 (94%) were viremic. On the other hand, as mentioned 
earlier in this chapter, a study by Allander and colleagues [56] on the full cohort 
of 258 wheezing children showed that 94% of the children with a high 
respiratory viral load (≥104 copies/ml) were viremic as opposed to only 11% of 
children with low load (<104 copies/ml). Together these associations indicate 
that HBoV1 viremia is a good marker of recent and, due to its association with 
high NPA loads, clinically most relevant HBoV1 infections.  
 However, these results do not necessarily mean that typical HBoV1 
primary infections are associated with viremia. The patients were enrolled based 
on hospitalizing respiratory symptoms and therefore represent the more severe 
spectrum of HBoV1 infections. The DIPP cohort provides a better model of 
typical HBoV1 infections among children but the long sampling interval of 2-6 
months inevitably downplays the incidence of viremias. Of the 94 DIPP children 
who demonstrated HBoV1 IgGa, 23 (24%) were found to be viremic. Viremias 
coincided almost invariably with HBoV1 IgGa and/or IgMa seroconversion; the 
few exceptions have been discussed in chapter 8.4. 
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The length of a typical HBoV1 viremia can be roughly 
approximated by combining the data of studies II-IV. According to the DIPP 
results (IV), none of the 24 children with viremia showed HBoV1 DNA in the 
follow-up sample taken 3 to 6 months later. Assuming that these 24 individuals 
are representative of the general population, this yields an upper limit for the 
duration of viremia for most immunocompetent children.  On the other hand, 
only 10 of the 44 (23%) wheezing children with HBoV1 viremia at the time of 
admission were still viremic 2-3 weeks after discharge (Study II; time at the 
hospital was 1-3 days). If it was assumed that the onset of viremia preceded 
hospitalization by a few days, then in most individuals HBoV1 viremia would be 
expected to last less than 3 weeks. If no association was assumed between 
HBoV1 and the onset of the wheezing symptoms, then on average the first 
sampling could be expected to have taken place in the middle of the viremic 
period. This means that, regardless of the association of HBoV1 with respiratory 
symptoms, in most individuals HBoV1 viremia lasts less than 6 weeks. 
Contrasted with the observations made in the Study IV on the 
exclusive occurrence of HBoV1 viremias in primary infections and in early 
childhood, a study by Bonvicini and colleagues described the presence of HBoV1 
in 6% of healthy adult blood donors [159]. Long persistence of HBoV1 DNA in 
blood would be in line with the kinetics of human parvovirus B19 viremia, which 
may persist for months and possibly even years in the blood of 
immunocompetent individuals [160,161]. However, Bonvicini and colleagues 
relied on a fluorescent DNA binding dye as the PCR product identification 
method. This method by itself is much more prone to false positive results than 
qPCRs based on hydrolysis probes, since SYBR green reacts with any double 
stranded DNA and the specificity of the assay relies solely on specific primer 
binding. Furthermore, the authors did not disclose any method (e.g. sequencing 
or melting point analysis) to verify their results. 
 
HBoV2-4 viremias. None of the 248 wheezing children were viremic for 
HBoV2-4 as observed in Study III. However, this needs to be put in the context 
of few acute HBoV2-4 infections among these children. Only 5 (2%) of the 248 
children showed an IgG seroconversion for HBoV2, 2 (0.8%) for HBoV3 and 
one (0.4%) for HBoV4. For comparison, 13% of these children showed an IgG 
seroconversion for HBoV1 and 19% [113] had HBoV1 viremia. Incidentally, these 
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data show that HBoV2-4 do not have a significant role in acute expiratory 
wheezing in Finland. 
 In the entire DIPP cohort of 109 children, 59 (54%) showed 
HBoV2 IgG seroconversion and 11 (10%) HBoV3 seroconversion. Only 3 (5%) of 
the children with HBoV2 seroconversion showed HBoV2 viremia (all coinciding 
with the HBoV2 seroconversion). One child of the 11 HBoV3 seroconversions 
(9%) had HBoV3 viremia. Viral loads were <104 copies/ml in all cases. As 
discussed in chapter 8.4, four HBoV2 viremias were also discovered in HBoV1 
seropositive children that did not result in a detectable IgGa response against 
the viremic species. The concentrations of viral DNA in the sera of these 
children were also low, <104 copies/ml. 
 In addition to studies III and IV, as outlined here, only two 
relatively small-scale studies addressing the occurrence of HBoV2-4 viremias 
have been published. Mitui and colleagues tested 79 serum samples from an 
equal number of children with encephalitis [162] and found HBoV2 DNA in one 
serum (with no other pathogen detected). Paloniemi and colleagues tested 
serum samples from six children with gastroenteritis and HBoV2 DNA in stool, 
and found viremia in two sera [163]. Neither study reported the quantity of viral 
DNA in the sera. 
   
Summary. HBoV1 viremia is a reliable marker of a very recent or acute HBoV1 
infection. HBoV1 viremia is also associated with IgG/IgM seroconversions and 
high NPA load. This and the seclusion of blood circulation from exogenous 
(contaminating) DNA makes viremia a good marker for diagnosing HBoV1 
infections. In contrast, HBoV2 viremias appear to be rare and to coincide 
infrequently with HBoV2 seroconversion. As discussed in the previous chapter, 
this may indicate that the enteric bocaviruses typically cause localized infections 
of the gastrointestinal tract and not systemic infections like HBoV1. 
8.7 CLINICAL CORRELATES OF HBOV INFECTION 
(IV) 
The scheduled sampling of the 109 DIPP children in study IV included an 
interview of the parents by a study nurse about any clinical symptoms or 
illnesses since the previous visit. This enabled us to compare symptom 
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frequencies in the HBoV seroconversion intervals to those in the neighboring 
intervals. However, before taking a closer look at the results, the following 
limitations need to be taken into account: 
 
1) The parents were not instructed to keep a daily diary about the children's 
symptoms to reduce recall bias. It is likely that the parents failed to recall all of 
the symptoms, especially those that were mild, after the 3-6 month sampling 
interval or confused them with the previous interval. Furthermore, of the signs 
and symptoms discussed here, only lower respiratory tract infections (LRTI) 
and acute otitis media were always diagnosed by a physician. Other symptoms 
were more often deduced from the notes of the interviewing study nurse. 
 
2) The statistical power of the analysis is limited by the small number of 
children involved. 
 
3) The presumed OAS effect may prevent us from correctly timing secondary 
HBoV infections. Furthermore, secondary infections may not be as strongly 
associated with symptoms as primary infections due to cross-protective 
immunity. 
  
With these limitations in mind, Table 11 shows three most commonly observed 
infection-related symptoms during HBoV1 primary seroconversions and during 
the neighboring sampling intervals, i.e. upper respiratory tract infection (URTI), 
gastroenteritis and acute otitis media. URTI was diagnosed when the child's 
parents reported cough or rhinitis and one or more of the following, sore throat, 
ear pain or in the case of infants, difficulty breathing or eating. Gastroenteritis 
was defined as diarrhea, vomiting or both. Acute otitis media was diagnosed by 
a physician. Other symptoms were observed too rarely for a meaningful 
assessment of statistical association. The full list of observed symptom types can 
be found in ref. [139].  
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Table 11. Infection-related symptoms during primary HBoV1 seroconversions (n=65; 
children with simultaneous HBoV2- or 3 seroconversion excluded) compared with 
neighbouring sampling intervals. 
 Interval  Next interval  Previous interval 
Symptom no. (%)  no. (%) p value  no. (%) p value 
URTI 30 (46)  20 (31) 0.09  31 (48) 0.86 
Acute otitis media 32 (49)  23 (35) 0.15  20 (31) 0.04 
Gastroenteritis 14 (22)  10 (15) 0.50  11 (17) 0.66 
Boldface indicates statistical significance by Liddell exact test (<0.05). URTI, upper respiratory tract 
illness. 
 Of the three symptoms shown, only acute otitis media was 
observed more frequently in the seroconversion interval than in either of the 
neighboring intervals. However, only comparison of the seroconversion interval 
to the previous interval yielded a statistically significant difference at the 0.05 
probability level. No association was observed between HBoV1 and URTI. This 
was rather surprising considering that a previous analysis this same cohort of 
children [139] (done without antibody absorption) showed a strong association 
between upper respiratory tract illness (URTI) and HBoV1 infection. Potential 
reasons for this difference are: 
 
1) Smaller number of children classified as having HBoV1 seroconversion. The 
previous study reported HBoV1 IgG seroconversion in 101 children (the 
remaining 8 were positive from birth). Study IV found that 15 of these 101 
seroconverted children actually had no HBoV1 IgGa during the entire follow-up 
period and were instead positive for HBoV2 or -3 IgGa.  
 
2) Better timing of HBoV1 infections in the present study; interval for HBoV1 
seroconversion changed in 12 children due to HBoV2-3 cross-reactivity 
 
3) Changes in the interpretation of symptoms fulfilling our criteria of URTI 
(from the notes of the study nurse) 
 
4) Improved blinding of the statistical data.  
 
Results and discussion 
 104 
 It would be tempting to speculate from the frequency of upper 
respiratory tract symptoms (<50%) in the HBoV1 seroconversion interval that a 
significant portion of HBoV1 infections does not result in these symptoms. After 
all, judging from the background symptom rates of the neighboring intervals, 
other pathogens probably contribute significantly to the symptom rate of 46% in 
the seroconversion interval. Mostly asymptomatic HBoV1 infections would be in 
line with most of the existing (DNA-based) literature on the etiology of the virus 
(chapter 5.2.6). However, the "low" incidence of symptoms in study IV is very 
likely downplayed by the parents' ability to recall symptomatic episodes and the 
limitations of the DNA studies have already been discussed extensively. 
Classification of upper respiratory tract infections is also subjective. Christensen 
and colleagues, the authors of a study indicating that the detection of 
respiratory HBoV1 mRNA is mostly limited to symptomatic individuals [98], 
classified rhinitis and otitis media (alone or in combination) as an upper 
respiratory tract infection. Our study took a more strict approach required the 
presence of i) cough or rhinitis together with fever, sore throat and/or ear pain 
or ii) the simultaneous presence of cough and rhinitis for the symptoms to be 
classified as an upper respiratory tract infection. It will be interesting to see 
whether the very high correlation between HBoV1 mRNA detection and 
symptoms observed by Christensen and colleagues will be replicated by others.  
 As opposed to URTIs that were reported by the parents and 
recorded by the study nurse, a physician diagnosed and recorded LRTIs. Of the 
65 children with primary (sole) HBoV1 seroconversion, 2 (3%) had LRTI 
compared to three children (5%) in both of the neighboring intervals. This data 
indicates that the absolute risk of LRTI in sole HBoV1 infections is quite low. In 
relative terms, however, the virus can be a significant causal agent in the 
etiology of LRTI. A recent study by Christensen and colleagues [98] found 
HBoV1 mRNA in 25% of 133 children with respiratory infections but none of the 
28 controls without respiratory symptoms. In fact, 31% of 86 children diagnosed 
with LRTI tested positive for HBoV1 mRNA and in 19% of the 86 children 
HBoV1 was the only respiratory virus found. 
 Turning now to HBoV2, Table 12 illustrates the infection-related 
symptoms during primary seroconversion by the virus. As expected from the 
presumed enteric nature of the virus, no association was observed with URTI or 
acute otitis media. The relative occurrence of gastroenteritis was higher in the 
seroconversion interval (31%) than in the neighboring intervals (13-18%) or, for 
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comparison, in the HBoV1 seroconversion interval (22%) without reaching 
statistical significance. Although the numbers of subjects are small and the data 
are probably affected by the said recall bias of the parents, it is tempting to 
speculate that HBoV2 may play some role in gastroenteritis whereas most 
infections by the virus are asymptomatic or subclinical. This data is in line with 
previous studies, mostly supportive of an association between HBoV2 DNA 
detection and acute gastroenteritis [26,93,100]. 
  
Table 12. Infection-related symptoms during primary HBoV2 seroconversions compared 
with neighbouring sampling intervals. 
 Interval     Next interval     Previous interval 
Symptom no. (%)  no. (%) p value  no. (%) p value 
URTI 14 (31)  18 (18) 0.61  14 (31) 1.0 
Acute otitis media 12 (27)  12 (27) 1.0  6 (13) 0.18 
Gastroenteritis 14 (31)  8 (18) 0.24  6 (13) 0.08 
URTI, upper respiratory tract illness.  
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9 CONCLUDING REMARKS AND FUTURE 
PROSPECTS 
Recent years have been witnessing the explosion of new viruses being found 
among humans and animals. The main reason for this is the remarkable 
innovation in sequencing technologies making random screening of microbial 
sequences economically feasible. As part of this systematic exploration of novel 
viruses, at least 14 new parvovirus species have been reported during the last 8 
years. 
Basic DNA and antibody detection tools are central in assessing the risk 
that these novel viruses may pose to human health. This thesis describes 
methods for detecting and quantifying the genomic sequences of all four 
recently discovered HBoV species.  The generation of recombinant HBoV1-4 
virus-like particles and their use in the study of HBoV immune responses were 
also demonstrated.  
Future longitudinal studies should address the duration of HBoV2 and 
HBoV3 shedding in stool to assess the diagnostic value of stool PCR.  Future 
research on the pathogenecity of these enteric viruses could perhaps also adapt 
the mRNA approach successfully used for the diagnosis of acute HBoV1 
infections. Detection of IgA responses is another as yet unexploited avenue in 
the research of these viruses.  
The data on children followed from birth to early teens demonstrated 
that HBoV1 seroconversion resulted in weak or absent species-specific immune 
responses against subsequent HBoV2 infections, and vice versa. This may be 
due to OAS, cross-protective immunity or a combination of both factors. In the 
absence of animal models for productive HBoV infections, the cross-protective 
properties of HBoV2-4 antibodies, or lack thereof, could be studied in the 
recently developed HBoV1 cell culture systems [33,108]. With respect to OAS, 
preliminary animal experiments by immunizing rabbits consecutively with 
heterologous or homologous HBoV VLPs have already been done  
(unpublished). The results were mixed; some immunizations resulted in strong 
IgGa responses against the secondary antigen, whereas others resulted (in line 
with OAS) in very weak secondary responses. It would be interesting to see 
these experiments replicated with minute doses of antigens to avoid the 
potential flooding effect discussed in chapter 5.3.2. Live viruses rather than 
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artificial virus capsids may also be required for OAS, if indeed a real 
phenomenon, to fully manifest itself.  
The DIPP cohort of Study IV could be a rich source of information well 
beyond what was discussed in this thesis. Analysis of the present data was 
limited by gaps in the qPCR testing of the serum samples (as selection was 
based on changes in EIA absorbances) and lack of antibody titer measurements. 
The omission of these analyses is understandable when one considers the 
laborious nature of the project; study IV alone represents some ~16 000 EIA 
and qPCR experiments. Future inclusion of these data would enable to i) 
address the (unlikely) possibility of non-immunogenic viremias as an alternative 
to OAS, ii) find more cases viremias among primed individuals, and to iii) 
identify secondary increases in antibody levels in a more sensitive and objective 
manner. This would yield a better understanding of the immunological 
interactions between consecutive HBoV infections. 
As we approach the end of this thesis, I cannot help but reflect back on 
my thoughts about virology during highschool. I thought at the time that a virus 
would be the perfect subject of biological reaserch for someone who would 
prefer to understand a system from top to bottom. Something small and simple 
enough without the uncertainties and massive amount of data involved in the 
research of more complex organisms. After years of reasearch on one of the 
smallest and at least structurally most simple viruses known and being 
overwhelmed by the extent of the literature and our own data, the irony is 
palbable. To make a circle back to the Carl Sagan quote that prefaced this thesis, 
we are not at the truth but closer to it, and have found new oceans (or at least 
reservoirs) of undiscovered possibilities in the process. 
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11 SUPPLEMENTARY DATA 
Supplementary Table 1. GenBank accession numbers used to construct the 
phylogenetic tree in Figure 2. 
Name GenBank ID 
Adeno-associated virus 2 AAS99314 
Aleutian mink disease virus AAS99314 
Bovine parvovirus NP_041404 
California sea lion bocavirus 1 AEM37603 
Canine minute virus ADA57646 
Gorilla bocavirus 1 YP_003799998 
Human bocavirus 1 YP_338088 
Human bocavirus 2 ABW79867 
Human bocavirus 3 ACR15791 
Human bocavirus 4 YP_002916062 
Human partetravirus ADM26646 
Human parvovirus B19 AAB47793.1 
Porcine bocavirus 1 ADP36998 
Raccoon parvovirus AAA47117 
 
Supplementary Table 2. GenBank accession numbers used to construct the 
phylogenetic tree in Supplementary Figure 1. 
Name GenBank ID 
Adeno-associated virus 2 AF043303 
Aleutian mink disease virus JN040434 
Bovine parvovirus DQ335247 
California sea lion bocavirus 1 JN420361 
Canine minute virus FJ214110 
Gorilla bocavirus 1 HM145750 
Human bocavirus 1 JQ923422 
Human bocavirus 2 FJ973558 
Human bocavirus 3 EU918736 
Human bocavirus 4 FJ973561 
Human partetravirus AY622943 
Human parvovirus B19 AY044266 
Porcine bocavirus 1 HM053693 
Raccoon parvovirus JN867610 
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Supplementary Table 3. GenBank accession numbers and geographical origins of 
sequences used to construct the DNA alignment for primer and probe design (Figure 
16). 
Virus Country of 
discovery 
GenBank ID 
HBoV China GQ926983 
HBoV China GU139423 
HBoV Germany FJ858259 
HBoV Hong Kong EF450740 
HBoV Sweden NC_007455 
HBoV Taiwan EU984233 
HBoV Thailand EF203920 
HBoV USA GQ925675 
HBoV2 Australia FJ948860 
HBoV2 Australia EU082213 
HBoV2 China GU301645 
HBoV2 China GU301644 
HBoV2 Nigeria FJ973560 
HBoV2 Pakistan GQ200737 
HBoV2 Pakistan FJ170279 
HBoV2 Pakistan GQ200737 
HBoV2 United Kingdom FJ170280 
HBoV3 Australia EU918736 
HBoV3 Australia FJ948861 
HBoV3 Australia NC_012564 
HBoV4 Nigeria NC_012729 
HBoV4 Nigeria FJ973561 
HBoV China GQ926983 
HBoV China GU139423 
HBoV Germany FJ858259 
HBoV Hong Kong EF450740 
HBoV Sweden NC_007455 
HBoV Taiwan EU984233 
HBoV Thailand EF203920 
HBoV USA GQ925675 
HBoV2 Australia FJ948860 
HBoV2 Australia EU082213 
HBoV2 China GU301645 
HBoV2 China GU301644 
HBoV2 Nigeria FJ973560 
HBoV2 Pakistan GQ200737 
HBoV2 Pakistan FJ170279 
HBoV2 Pakistan GQ200737 
HBoV2 United Kingdom FJ170280 
HBoV3 Australia EU918736 
HBoV3 Australia FJ948861 
HBoV3 Australia NC_012564 
HBoV4 Nigeria NC_012729 
HBoV4 Nigeria FJ973561 
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Supplementary Figure 1. Partial neighbor-joining tree of the Parvovirinae subfamily 
based on the amino acid sequences of the NS1 protein. Genus Bocavirus is shown in 
red and has been expanded to show most species within the genus, whereas only one 
exemplary species is shown from the other genera. Sequences were aligned with 
Geneious 4.8.5 aligner using blosum62 cost matrix with gap open penalty of 12 and gap 
extension penalty of 3. The tree is derived from 100 bootstrap replicates and bootstrap 
values ≥70% shown. The scale bar represents 0.2 average amino acid substitutions per 
site. 
 
Supplementary Figure 2. Simulation EIA data with 350 lognormally distributed random 
values. Means and standard deviations (STDEV) of the two different data sets are 
indicated in the image. The data was generated with the lognrnd function of MATLAB 
and Statistics Toolbox Release 2012b, The MathWorks, Inc., Massachusetts, United 
States. STDEV, standard deviation. 
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Supplementary Figure 3. Schematic illustration of HBoV2-4 absorption EIA assays. OD, 
optical density; VLP, virus-like particle. 
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